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Abstract 
For industrial recombinant-protein processes, protein refolding and purification are crucial 
steps towards the recovery of considerable numbers of active and safe therapeutic products. 
In this thesis, intensification strategies for protein refolding and purification processes are 
explored. Development of an intensified process aims at simultaneous optimization of 
process performance indicators, namely: refolding yield, product purity, volumetric 
productivity and solvent consumption which in turn decrease the cost and time constraints to 
market. 
The first strategy investigated related to multivariable experimental work using size 
exclusion chromatography (SEC) as a refolding method and a denatured/reduced model 
protein (lysozyme). SEC was selected due to its potential for refolding of higher 
concentrations of protein compared to conventional refolding methods used currently in 
industry. The investigated variables were protein loading concentration, refolding buffer 
composition including pH, sodium chloride salt and ʟ-arginine, aggregation prevention 
additive, concentrations. The interplay of these process variables was studied and it was 
shown when ʟ-arginine is used, over the experimental space, the effects of pH and protein 
loading concentration on refolding yield are insignificant. This observation introduced the 
possibility of manipulating pH in a wider range without concerns for protein aggregation; for 
instance, to adjust the redox potential of the buffer without the need for costly redox couple 
chemicals to assist reformation of disulfide bridges in oxidative refolding of the protein. The 
results also provide more experimental evidence on the mechanism of aggregation prevention 
by ʟ-arginine.  Secondly an experimentally-verified model of oxidative protein refolding on 
SEC was developed, with the goal of high-throughput process screening and optimization 
using the aforementioned model.  Model development involved exploration of methods to 
find characteristic information on short-lived refolding kinetic species and lysozyme 
oxidative refolding kinetic schemes and constants under the two studied refolding 
environments, namely with and without ʟ-arginine additive. It was shown that ʟ-arginine 
prevents aggregation without considerable impact on the kinetics of lysozyme oxidative 
refolding. 
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Finally, SEC in a multi-column continuous simulated moving bed configuration (SMB-SEC) 
was evaluated to fully exploit the potential of SEC for intensified protein refolding and 
purification. This configuration offers several advantages compared to single-column 
operation, including increased productivity per unit mass of solid phase, lower solvent 
consumption, and less diluted products, provided that operation parameters are screened and 
tuned for simultaneous optimization of process performance indicators. In this phase of the 
project, the effect of scale-up was predicted and considered for modifying and utilizing 
single-column model towards design/operation of a SMB-SEC. This thesis presents a 
framework for protein refolding and purification process development and optimization, 
including reduced cost of chemicals, improving the refolding yield, high-throughput 
measurements of parameters and finding a suitable reaction scheme of refolding and 
aggregation for mathematical model development applicable to both single-column and 
multi-column continuous operations, and defining appropriate process performance 
indicators for optimized operation of SMB-SEC. 
Keywords 
Inclusion-body-based protein; Intensified oxidative protein refolding; Mathematical 
modeling; Multi-column continuous simulated moving bed. 
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Chapter 1  
  
 2 
 
1 Introduction 
1.1 Recombinant-protein Technology 
The advent of recombinant DNA-technology in the 1970s opened the possibility of 
engineering and expressing valuable protein/peptide products using a host cell. 
Recombinant human insulin and growth hormone were first introduced to the market in 
the early 1980s improving the availability, quality and safety aspects of these products 
which before were only available by tissue extraction from plants and animals [1]. The 
market for recombinant bio-pharmaceuticals has been growing rapidly standing at 30 
products with an estimated market value of 50 to 60 billion USD in 2004 [2] and reaching 
to more than 151 unique products approved by the Food and Drug Administration (FDA) 
and/or European Medicines Agencies for different clinical indications by 2012 [3]. 
Manufacturing of the biopharmaceuticals, including the above mentioned products, 
involves drug discovery, expression of the desired product in the host cell (upstream), 
cell line production (midstream), recovery and purification of active and pure product 
(downstream) and drug formulation. These stages are integrated and it is important that 
all phases of process development be designed in tandem for instance, screening the drug 
candidates considering both efficacy and downstream processing requirements. 
Otherwise, downstream operations can account for over 70% of the production cost as 
they are greatly impacted by the presence of impurities and contaminants [4]. 
For recombinant-protein production, selection of host cells includes prokaryotes, yeast, 
filamentous fungi, insect and mammalian cells. About 30% of the recombinant-protein-
therapeutics are expressed in Escherichia coli (E.coli) due to its well-characterized 
genetics, rapid growth and high level of expression, and low cost media; the level of 
expressed product can reach up to 50% of the cell mass [1,3]. However, when E.coli is 
used to express a protein of interest, due to over-expression and lack of necessary 
condition (e.g. saturation of cell folding machinery), the protein molecules may not fold 
to their unique three-dimensional structure known as native functional conformation. The 
expressed unfolded/partially folded polypeptide chains are prone to intramolecular 
 3 
 
interactions and aggregation. Particularly, when the expressed polypeptide chains contain 
cysteine residues, formation of intramolecular disulfide bridges under over-expressed 
condition promotes aggregation inside the cell [3,5]. These aggregates are called 
inclusion-bodies (IBs); they are insoluble and contain large amount of inactive protein. 
Table 1-1 shows some examples of therapeutics produced as IBs [1]. 
Table 1-1. Examples of IBs produced using recombinant DNA technology 
Molecule Companies Indication 
rh Insulin and analogs Eli Lilly, Aventis Diabetes treatment 
Interferon alfacon-1 Valeant Anti-viral 
Anti-tumor 
Anti-inflammatory 
  
r Interferon β-1b Schering AG, Chiron 
r Interferon γ-1b Genentec 
Intermune 
rh IL-1 receptor -antagonist Amgen Immunotherapeutic-  
agents 
 
r IL-2 Chiron 
r IL-2-diphtheria toxin fusion Seragen / Ligand 
r IL-11 Genetics Institute 
r Human growth hormone (r 
hGH) 
Genentech, Eli Lilly, 
Pfizer, Schwartz- 
Pharma, Novo 
Nordisk 
 
growth hormone 
deficiency
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1.2 Downstream Processing of Inclusion-body-based Protein 
Figure 1-1 illustrates the common route for downstream processing of IBs. After cell 
harvest and disruption, IBs are easily separated from the impurities in the cell broth as 
they are usually heavier than other cell components resulting in low level of impurities 
(70-90% of total protein is often present in IBs) [3,5]. The separated IBs are commonly 
further processed by addition of chaotropic reagents (i.e. denaturing and reducing agents 
such as urea and DTT) or adjusting the pH of the buffer (pH induced solubilization) to 
break the intra-molecular bonds and dissolve aggregates. The latter method of 
solubilization is considered more economical but its applicability is limited and depends 
on the nature of the aggregates as not all IBs are dissolved by adjusting the pH [6]. Once 
aggregates are dissolved and unfolded protein monomer is obtained further downstream 
processing aims at recovering the protein monomer in its folded functional conformation 
(protein refolding) and eliminating remaining contaminates from the host cell if they are 
not separated during IB recovery as well as soluble aggregate impurities that might be 
formed during the process. Similar to in-vivo refolding of unfolded/partially folded 
polypeptide chains, the in-vitro refolding is also susceptible to aggregation and 
misfolding. In other word, the correct folding pathway competes with aggregation and 
misfolding. Separation of soluble aggregates is crucial as they can cause unwanted 
autoimmune responses [7–9]. These species are also linked to neurodegenerative diseases 
such as Alzheimer and Parkinson; ongoing research suggest that protein aggregation 
formation may be a symptom of the disease rather than cause of the disease [10]. 
Accordingly, if aggregates cannot be reduced to an acceptable level below the World 
Health Organization limits, a protein with therapeutic potential may be dropped from 
development. 
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Figure 1-1. Downstream processing of inclusion bodies (IBs) 
1.2.1 Protein Refolding Methods 
Refolding strategies have involved two main categories to date, namely dilution and 
separation. In both cases reduced local concentration of denaturing and reducing agents 
surrounding unfolded protein molecule promotes formation of folded conformation. 
Batch dilution is considered the easiest method and used in industrial operation; however, 
the working concentrations are low to avoid aggregation formation which in turn results 
in higher buffer consumption, low volumetric productivity, handling large volumes and 
additional concentration steps [6]. Various matrix assisted chromatography (MAC) 
methods such as ion-exchange, hydrophobic, affinity and size exclusion chromatography 
(SEC), have been used at lab scale as separation methods [11–14]. MAC methods allow 
for higher protein concentrations to avoid aggregation due to spatial isolation of unfolded 
molecules while adsorbed on the matrix surface or gradual separation of chaotropic 
reagents from unfolded protein molecules. Although MAC techniques are also 
accompanied by dilution, considering the lower dilution factor and higher loading 
concentrations compared to dilution method, they result in more concentrated product. In 
Bioreactor 
Cell harvest & 
disruption 
Removal of cell 
debris 
IBs wash 
IBs solubilization 
Protein refolding& 
purification 
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addition, the possibility of separation of impurities within the same unit holds a promise 
to eliminate the need for further processing to meet the standards in terms of impurity 
levels. Among different matrix assisted methods, SEC is a non-adsorptive technique and 
separation is achieved by different migration velocities according to the size of the 
species. The negligible interaction with the matrix may be advantageous compared to 
adsorptive methods. For instance, ion exchange chromatography may result in low 
recovery [15] unless multiple gradient schemes in terms of buffer pH, urea and salt 
concentrations are used [16]. Depending on properties of the adsorptive surface and 
protein, protein might remain unfolded and tend to aggregate while adsorbed on the 
surface. In these cases the highest productivity is achieved by low contact time with 
matrix and off-column refolding [17,18]. In contrast to hydrophobic chromatography, 
protein refolding on SEC requires refolding buffer containing low concentration of salt to 
prevent non-specific interactions [19], while high salt concentration requirement for 
protein binding in hydrophobic chromatography may be problematic when working with 
unfolded protein due to reduced solubility of these species compared to native 
conformation [5,20]. For these reasons, SEC has been considered for potential intensified 
protein refolding and purification and has been used at lab scale both in the form of batch 
single-column processing and multi-column continuous simulated moving bed operation 
(SMB-SEC) [6,19,21–27]. 
1.2.2 Fundamentals of Protein Folding/Refolding 
In 1972 Christian B. Anfinsen (1972 Chemistry Nobel Prize) showed that native proteins 
can be unfolded using denaturing condition (e.g. breakage of disulfide bridges) but this 
unimolecular reaction can be reversible and native conformation of the protein is 
recovered under non-denaturing conditions [28]. Anfinsen’s work resulted in the 
assumption that the native state is thermodynamically the most stable conformation under 
suitable conditions. However, this general acceptance was challenged by experimental 
protein aggregation studies. Baldwin et al. [29] observed that  regardless of the sequence 
of the protein, when protein concentration surpassed a critical solubility concentration 
they aggregate to form amyloid fibril, a structure rich in β-sheet content, indicating that 
amyloid fibril is the most stable conformation . In the same work the cellular 
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concentration of the proteins under the study were compared to their equilibrium 
concentration and found to be higher than equilibrium concentrations. The question 
raised in this work is: how proteins have evolved to avoid aggregation during their 
normal life span in-vivo? One suggestion is that the native protein in cell is metastable 
compared to amyloid fibril and there is a large kinetic barrier between folded functional 
and aggregate states. Consequently, protein stability is controlled both 
thermodynamically and kinetically [29,30] yet there is no clear understanding that what 
causes kinetic stability of the protein inside the cell [31]. The overall stability of the 
native protein is the result of enthalpic (e.g. ionic bonds, hydrogen bonds and Van der 
Waals forces) and entropic contributions (release of disordered water molecules due to 
hydrophobic effect) that balance the large conformational entropy penalty associated with 
folding [32]. The native state is usually not much more stable than unfolded state and 
slight changes of the above mentioned interactions can induce unfolding such as 
temperature variation and chemical composition of the solvent.  
Protein folding/refolding pathway has been classified to two main categories namely 
cooperative and non-cooperative. The former involves only two states (unfolded and 
folded) whereas the latter involves at least one intermediate state. Many proteins, 
especially small single domain species with less than 100 amino acids, fold in a two-state 
fashion [33]. However, larger proteins tend to deviate from two-state behavior. For 
example, the refolding of the model protein used in this work (lysozyme composed of 
129 amino acids) involves a “collapse process” and at least one kinetic intermediate. 
There have been controversial approaches in describing collapse process (burst phase) 
[34]. The question is whether this phase represents a folding/refolding step or is a 
reflection of sudden change in the solvent properties and involves non-specific 
interactions. The latter description is supported by experimental evidence on observation 
of burst phase for proteins that cannot fold [35] whereas some research work debate 
specific nature of collapsed conformation (i.e. early intermediates) [36]. Further details 
regarding mechanism of lysozyme refolding and aggregation is provided in sections 3.2.2 
and 4.2.3.  
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1.3 Research Contributions 
Despite extensive experimental work and successful utilization of SEC at lab scale for 
protein refolding and purification, there is still work to be done to consider feasibility for 
industrial application of this technology. Major contributions of this work to the research 
field are outlined here and found in chapters 2, 3 and 4 of this thesis in more details. 
Chapter 2: Multi-variable Operational Characteristic Studies of On-column 
Oxidative Protein Refolding at High Loading Concentrations [37] 
The first contribution from this thesis relates to quantifying the interaction of ʟ-arginine 
additive with refolding buffer pH and model protein loading concentration (lysozyme). A 
synthetic feed (denatured/reduced lysozyme obtained by addition of denaturing and 
reducing agents to naturally occurring lysozyme) was used throughout this work. The 
rationale for this approach was that regardless of the source of the protein (naturally 
occurring or recombinant), the refolding task involves dilution/separation of denaturing 
and reducing reagents from unfolded protein monomer.  Lysozyme has been extensively 
studied as a model system for oxidative refolding due to importance of disulfide bond 
formation in considerable number of proteins. 
 It was shown that the effect of both pH and protein concentrations on the refolding yield 
in the presence of low concentrations of ʟ-arginine (0.2 M) are trivial. In addition, in the 
presence of this additive and high protein loading concentrations (40 mg/mL) pore 
accessibility was reduced. Observations made in this study provided more experimental 
evidence towards the suggested mechanism of protein aggregation suppression by ʟ-
arginine and introduced the possibility of manipulating pH for adjusting the reducing 
potential of the buffer in oxidative refolding of the proteins, thereby potentially 
eliminating the need for an expensive redox couple commonly used in refolding 
practices. 
Chapter 3: Oxidative Protein Refolding on Size Exclusion Chromatography at High 
Loading Concentrations: Fundamental Studies and Mathematical Modeling [38]. 
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The second contribution is the development of an experimentally-verified mathematical 
model of oxidative protein refolding on SEC for fast screening of process parameters. A 
detailed kinetic scheme was investigated and various methods including quenched and 
equilibrium experiments as well as application of model compounds were introduced to 
obtain characteristic information on refolding kinetic species. It was demonstrated that 
characteristic information obtained from experiments on SEC may be erroneous due to 
non-specific interaction of species with the matrix. Kinetic studies showed an apparent 
two-state kinetic scheme including early intermediates and the native protein is 
significantly more accurate compared to commonly simplified mechanism including 
native-like intermediate to native protein. In addition under two explored chemical 
environments, namely with and without ʟ-arginine, the mass transfer characteristic and 
kinetic studies showed that low concentration of ʟ-arginine (0.2 M) increases the 
refolding yield of lysozyme with no considerable impact on the kinetics but did effect the 
mass transfer characteristics of lysozyme in SEC. 
Chapter 4: Oxidative protein refolding on size exclusion chromatography: From batch 
single-column to multi-column counter-current continuous processing. 
The third contribution from this thesis comes from introducing modifications into the 
model developed in the previous chapter in order to expand its applicability for prediction 
of protein behavior through columns connected in series in a SMB-SEC as a scale-up 
method. Aggregation was incorporated into the model to consider for higher local protein 
concentrations in SMB-SEC, due to the lower dilution factor in this system compared to 
the single-column operation. It was demonstrated that in a wide working concentration 
range the refolding/aggregation is best described as occurring when local protein 
concentration is equal or higher than a critical concentration (i.e. solubility of early 
intermediates), which can be measured. Examining the local denaturant concentration 
through the SMB-SEC confirmed the findings of previous research work that a model 
with constant kinetic and thermodynamic parameters may not provide an accurate 
estimate of early intermediate to native protein ratio at the product outlet. It was also 
shown that an unfolding reaction should be added to consider the higher local 
concentration of denaturant which occurs due to lower dilution factor compared to single 
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column. Based on predictions of the denaturant concentration at the product outlet it was 
concluded that the refolding reaction will continue off-column. Accordingly, process 
performance indicators were defined based on solubilized protein (early intermediates 
and functional native protein) which does not require differentiating between the 
solubilized conformations. This work demonstrated that a model with constant 
parameters is suitable for screening the operation parameters and optimization of the 
performance of a SMB-SEC unit if these effects are taken into account.  
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2 Multi-variable Operational Characteristic Studies of On-column 
Oxidative Protein Refolding at High Loading Concentrations 
Abstract 
Chromatographic-based protein refolding techniques have proven to be superior to 
conventional dilution refolding methods, due to the higher loading concentration and 
simultaneous purification. Among these techniques, Size Exclusion Chromatography 
(SEC) has in particular been demonstrated as an effective method for refolding of variety 
of proteins. To date existing studies of protein refolding at high concentrations (>1 
mg/mL) in SEC have primarily been conducted as single factor studies, in which a single 
parameter is varied to assess impact on operating performance, which does not allow for 
determination of the interactions of different operating parameters and optimized 
operating conditions. In this work a multi-variable investigation of size exclusion protein 
refolding at high protein concentration using lysozyme as a model protein was 
performed, in order to quantify the interaction of factors and optimize performance. It 
was observed when ʟ- arginine is used as an additive the refolding yield becomes 
independent of the protein concentration and refolding buffer pH, providing that a redox 
couple is used to assist the reformation of disulfide bridges. Furthermore, the pore 
accessibility for small molecules was reduced in the presence of this additive particularly 
at higher protein concentrations indicating slower removal of these molecules and a 
possible additional mechanism of aggregation prevention. Using the subsequent 
optimized refolding buffer, a refolding yield of more than 90% was obtained for up to 40 
mg/mL loading concentration of lysozyme which has only been reported for a urea 
gradient SEC (8-2 M) with lower equilibration and elution flow rates due to high 
viscosity of buffer containing high concentrations of urea. 
2.1 Introduction 
Proteins are one of the most important biological compounds and beneficial to human 
health when used as therapeutic agents. Recombinant DNA technology continues to be 
one of the common methods in industry for production of many biopharmaceuticals, 
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including proteins [1]. In particular, Escherichia coli (E. coli) is one of the most used 
microbial expression systems in biotechnology due to its well characterized genetics, 
very high expression level and ease of manipulation [2]. One of the primary issues 
resulting from protein expression in E. coli is the formation of inactive protein aggregates 
(inclusion bodies). These aggregates require solubilisation through providing an 
environment for protein chains to unfold, which may be accomplished by using 
denaturing and reducing agents. After unfolding and aggregate collapse, the refolding of 
proteins into their compact structures is critical in order to restore biological activity and 
functionality. Refolding by dilution is commonly practiced in laboratories and industry 
due to its simplicity in design and operation [3–5]. However the correct protein folding 
pathway often competes with misfolding and aggregation, particularly at high 
concentrations which substantially reduces refolding yield. Furthermore, the presence of 
aggregates in the final product as impurities provides health concerns for utilization as 
therapeutics [6]. Consequently, the dilution technique has serious drawbacks during 
scale-up due to requiring low product concentrations and purity in addition to large 
process volumes, which necessitate additional cost-intensive post-refolding concentration 
and purification steps. These challenges limit high throughput production of therapeutic 
proteins and the speed with which new protein drugs can be brought to market [3]. 
Recently, chromatographic based refolding [3,7–9] has drawn great attention to address 
the challenges associated with product dilution, by facilitating spatial isolation of protein 
molecules and unfolding agents based on different affinity for solid phase or molecular 
size. These methods allow for protein refolding at higher concentrations and 
simultaneous protein purification due to reduced intramolecular interactions in adsorptive 
chromatography methods and gradual separation of protein and unfolding agents waves 
in non-adsorptive size exclusion chromatography (SEC). Among various 
chromatographic methods, SEC offers many advantages and has been widely used at lab 
scale for protein refolding in either batch or continuous mode [3,10–15]. The 
performance of SEC in terms of refolding yield, protein recovery and purity depends on 
many parameters, such as: protein structure, protein concentration, loading state of non-
native protein (e.g. denatured, denatured and reduced), column packing specifications 
(e.g. material, particle size, pore size), refolding buffer composition including its pH, 
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redox potential, ionic strength and additives’ concentrations [14–19]. However, the 
majority of research related to operational characteristics of SEC refolding pursued one-
factor-at-a-time approach which cannot quantify the interactions of factors preventing 
determination of optimal operating conditions. In this work, a multi-variable study of key 
parameters on SEC refolding at high concentrations was carried out, using lysozyme as a 
model protein.  
2.2 Design of Experiments 
A suitable refolding buffer is particularly critical in refolding of proteins. The refolding 
buffer reported to give highest refolding yield for lysozyme is comprised of 0.1 M Tris, 1 
mM EDTA, 2 M urea, 3 mM cysteine, 0.3 mM cystine or the same concentration of 
glutathione redox couple buffered at pH 8.1 [15]. In this work, the reported refolding 
buffer (0.1 M Tris, 1 mM EDTA, 2 M urea, 3 mM cysteine, 0.3 mM cysteine buffered at 
pH 8.1) was initially used to identify protein concentrations at which aggregates are 
formed. This is followed by a buffer optimization process to minimize the aggregation 
and increase the refolding yield. ʟ- arginine is commonly used to increase the protein 
mass recovery in various liquid chromatography columns [20,21] and has been proven to 
be an effective aggregation suppressor due to its unique effects on protein association and 
folding [22–26]. Higher concentrations of ʟ- arginine results in higher refolding yields, 
but it also slows down the rate of refolding [24,25]. Therefore, the concentration of ʟ- 
arginine was selected as one of the key factors which affect the refolding yield of 
lysozyme by SEC. Apart from ʟ- arginine concentration, refolding buffer pH, ionic 
strength and protein concentration are the other key factors which dictate the refolding 
yield of lysozyme [14,15,17,19]. A two-level full factorial design of experiment 
combined with replicated center point runs to test for curvature was executed in the 
current work to investigate the effect of the aforementioned operating parameters and the 
potential interactions between these factors. An empirical equation was developed to 
predict the refolding yield in the experimental space and search for optimum within the 
design space. 
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2.3 Materials and Methods 
2.3.1 Chemicals 
Reagent grade ʟ- arginine and urea, Ethylene Diamine Tetra Acetic acid (EDTA), 
lysozyme from chicken egg white, trizma® base (Tris-base), ʟ- cysteine, ʟ- cystine, Bio-
Ultra dithiothreitol (DTT) solution, Micrococcus lysodeikticus, potassium phosphate 
monobasic and BioXtra sodium chloride were purchased from Sigma-Aldrich, Canada. 
Red660™ protein assay reagent was purchased from G-Biosciences, USA. 
Superdex™75pg resin (24-44 µm) was purchased from GE healthcare, Canada.  
2.3.2 Feed Preparation 
Unfolding buffer (0.1 M Tris-base, 1 mM EDTA, 6 M urea and 32 mM DTT, pH 8.1) 
was used to prepare various concentrations of denatured and reduced lysozyme. The 
sample was incubated for 2-4 h at 37 °C to ensure loss of activity which was confirmed 
by enzymatic activity test as described below [15]. 
2.3.3 Refolding by Size Exclusion Column 
XK16/40 column (GE healthcare, Canada) was packed with Superdex™75pg resin. The 
total volume of column was 44mL and the packing quality was tested by comparing the 
peak symmetry and number of theoretical plates per length of column with manufacturer 
recommended criteria using 2% (v/v) acetone injection. The packed column was installed 
on ÄKTA purifier 100, controlled by UNICORN 5.31 software equipped with online pH 
probe, UV detector and conductivity cell. The fractionation kit allows the collection of 
samples at desired volumes. The column was equilibrated with 2 column volumes (CV) 
of refolding buffer prior to protein injection. After equilibration, 0.5 mL of denatured and 
reduced lysozyme was injected and eluted for 1.5 CV with refolding buffer at 1 mL/min 
flow rate. During elution fractions of 7 mL were collected and stored at 4 °C before 
analysis which was conducted in less than 24 h. The stability of samples during storage 
was tested by comparing the enzymatic activity of samples analysed immediately and 
stored ones which showed no significant difference  [27]. The fractions were pooled to 
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measure total protein recovery (𝑅𝑏%), refolding yield (𝑌%) and purity (𝑃𝑏%) as defined 
below. 
𝑅𝑏 =
𝑀𝑡𝑜𝑡𝑎𝑙
𝐿𝑉𝑖𝑛𝑗
 
(2-1) 
𝑌 =
𝑀𝑛𝑎𝑡𝑖𝑣𝑒
𝐿𝑉𝑖𝑛𝑗
 
(2-2) 
𝑃𝑏 =
𝑀𝑛𝑎𝑡𝑖𝑣𝑒
𝑚𝑜𝑛𝑜
𝑀𝑡𝑜𝑡𝑎𝑙
𝑚𝑜𝑛𝑜  
(2-3) 
 
where Mtotal and Mnative are total protein and equivalent native protein mass collected in 
pooled fractions associated with either all forms of protein or protein monomer which 
were measured by total protein and enzymatic activity assays as described in analytical 
methods, Vinj is injection volume, L is lysozyme loading concentration. 
The column was then washed with 2 CVs de-ionized water after elution. In case of in-
column protein precipitation and flow blockage, the column was washed with 6 M urea, 
32 mM DTT, 0.1 M Tris-base buffered at pH 8.1 at very low flow rates (< 0.2 mL/min) 
to dissolve the precipitated aggregates. 
All the buffers were prepared fresh using ultra-pure water (Barnstead easy-pure RODI 
equipped with 0.2 µm filter, Fisher Scientific), filtered again with a 0.2 µm membrane 
and de-gassed prior to use. 
2.3.4 Analytical Methods 
2.3.4.1 UV Absorbance 
The lysozyme powder was dissolved in 0.1 M potassium phosphate and 0.15 M NaCl 
buffer (pH 7) and the lysozyme content was determined by ultraviolet (UV) absorption 
spectroscopy (Shimadzu UV-3600) at 280 nm using extinction coefficient of 2.63 
mL/mg/cm.
 
The feed concentration (denatured and reduced lysozyme) was confirmed 
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using extinction coefficient of 2.37 mL/mg/cm. Feed samples were diluted in 0.1 M 
acetic acid [27]. 
2.3.4.2 Enzymatic Activity 
In order to determine the concentration of equivalent native protein (activity recovery) in 
pooled fractions, the enzymatic activity of samples were compared with enzymatic 
activity of standard protein samples prepared in the same buffer as used for on-column 
refolding. The enzymatic activity was measured by recording the linear decrease of cell 
suspension absorbance (0.15 mg/mL Micrococcus Lysodeikticus in 0.1 M potassium 
phosphate buffer, pH 7) at 450 nm for 40 s [15], with all measurements in triplicate.  
2.3.4.3 Total Protein Concentration 
The total protein concentrations in pooled fractions were determined using Red 660™ 
protein assay in which 50 µL protein samples was transferred to a test tube. 1 mL of 
reagent was added and mixed. The absorbance of the mixture was measured at 660 nm 
after 5 min. The total protein concentrations were calculated by comparing the sample 
and standard absorbance.  
2.4 Results and Discussions 
2.4.1 SEC Refolding of Lysozyme 
Figure 2-1 (A and B) illustrate the chromatograms of SEC refolding of lysozyme at 
various protein concentrations (5-40 mg/mL) using refolding buffer of 0.1 M Tris, 1 mM 
EDTA, 2 M urea, 3 mM cysteine, 0.3 mM cystine. The fractions associated with 
aggregates and protein monomer were pooled to measure total protein recovery and the 
protein monomer fraction pool was used to measure purity and refolding yield as defined 
earlier, with the results summarized in Table 2-1. As expected, increasing protein 
concentration decreased the refolding yield due to the aggregation. However, under the 
current operating conditions (e.g. gel pore size, elution flow rate, refolding buffer 
composition), the aggregates are soluble and completely separated from protein monomer 
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in SEC column based on size, with larger aggregate molecules eluting before monomers. 
Therefore, close to 100% purity of protein monomer was attainable, highlighting the 
advantage of SEC for simultaneous protein refolding and purification after refolding. The 
last peak in all chromatograms corresponds to DTT, which due to low molecular weight 
can penetrate deeper in the gel pores. 
 
Figure 2-1. Chromatograms of SEC refolding of lysozyme (A) at low loading 
concentrations, (B) at high loading concentrations. Peaks from left to right: aggregate(s), 
protein monomer and DTT. 
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Table 2-1. SEC operating conditions, total protein recovery (𝑅𝑏%), refolding yield (𝑌%) 
and purity (𝑃𝑏%) 
L (mg/ml) Minj (mg) Mtotal (mg) Mnative (mg) 𝑅𝑏 (%) 𝑃𝑏 (%) 𝑌 (%) 
4.5 2.25 2.3 2.48 100 100 100 
9.05 4.52 4.47 4.3 98 100 95 
18.26 9.13 9.56 7.7 100 100 84 
36.03 18.01 16.1 11.37 89 95 63 
 
2.4.2 Multi-variable Studies of Refolding of Lysozyme at High 
Concentration 
A polynomial with linear and interaction terms was fit to measured experimental 
conditions to correlate the refolding yield (Y%) to lysozyme protein concentration (L) 
(20-40 mg/mL), refolding buffer pH (B) (8.1-9.5), NaCl salt (S) (0-0.2 M), ʟ- arginine 
(A) (0-0.2 M) concentrations and their significant interactions. Table 2-2 reports the 
model coefficients, along with 95% confidence interval.  
The analysis of variance (ANOVA) of the developed empirical fit showed the overall 
probability of 0.0001 which translates to 99.99% confidence that the coefficients are not 
zero. The model terms have p-values smaller than 0.05 indicating their significance 
within 95% confidence interval. Probability plots showed normal distribution of error 
and, as shown in Figure 2-2, good agreement between predicted and experimental results 
is achieved using this model for refolding yield >10%. 
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Table 2-2. Estimated empirical fit parameters and their confidence interval 
Parameter Fit Coefficient Relative Confidence- interval (%) 
Intercept 54.55 7.06 
L -13.78 29.95 
B -10.53 39.59 
S -18.16 22.97 
A 11.21 37.19 
LS -5.84 70.69 
LA 5.78 71.38 
BA 8.28 50.35 
SA -10.59 39.38 
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Figure 2-2. Experimental and predicted SEC refolding yield. The predicted SEC 
refolding yield was obtained using empirical fit. 
The fit coefficients for individual parameters suggest that higher refolding yields are 
attained at low protein concentration, salt concentrations, refolding buffer pH and high ʟ-
arginine concentrations. However, as Figure 2-3 (A and B) shows when 0.2 M ʟ- arginine 
is used as an additive in the refolding buffer protein concentration and refolding buffer 
pH demonstrated insignificant effect on the refolding yield in the experimental range 
tested in this work. 
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Figure 2-3. 3D surfaces generated using empirical fit; (A) pH = 8.8, no salt, redox couple 
(3 mM cysteine, 0.3 mM cystine) (B) Concentration = 30 mg/mL, no salt, redox couple 
(3 mM cysteine, 0.3 mM cystine). Y: refolding yield, L: lysozyme concentration, B: 
refolding buffer pH and A: L-arginine concentration. 
High protein concentration can reduce the refolding yield due to increased intra-
molecular interactions and protein aggregation. The refolding buffer pH influences the 
ionic interactions and redox potential of the system and is recognized as one of the most 
influential parameters in protein refolding. For lysozyme refolding, working at pH 9.5 
decreased the refolding yield compared to pH 8.1. Although negligible amount of 
solubilized aggregates were formed at pH 9.5 (Figure 2-4), aggregation was observed 
outside the column in the fractions associated with protein monomers. Working at pH 
closer to protein isoelectric point (11.35) presumably reduces electrostatic repulsion and 
protein solubility, which can result in the aggregation of unfolded, intermediate or native 
species. 
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Figure 2-4. Chromatograms of SEC refolding of lysozyme at 20 mg/mL loading 
concentration and pH 9.5. 
However, when ʟ- arginine is used, formation of protein-associated arginine clusters 
“crowds out” the protein molecules and prevents self-association and aggregation 
[22,23]. As shown in Figure 2-5 (A and B) no aggregates were formed independent of 
lysozyme loading concentration and refolding buffer pH .It was hypothesized that the 
overlapping peak eluting before refolded lysozyme is an ensemble of early kinetic 
intermediates with only a fraction of correct disulfide bridges, little structure and buried 
tryptophan residues [28]. Refolding without a redox couple results in the recovery of 
species with similar characteristics by preventing rearrangement and formation of correct 
disulfide bonds [29]. Therefore, the refolding was also conducted without redox couple to 
gain more information on the species eluting before refolded protein. As Figure 2-5 (C) 
illustrates, at pH 8.1 no refolded lysozyme was recovered when the redox couple was 
removed and the eluting peak has the same retention volume as the first peak in the run 
with the redox couple (Figure 2-5B). The enzymatic activity test of the protein pool also 
confirmed no activity recovery. The higher redox potential at pH 9.5, allows for the 
refolding to proceed even without redox couple and self-association is prevented due to 
the presence of ʟ- arginine. However, the reaction is slightly slower and the first eluting 
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peak is more populated. Nevertheless, its elution volume is identical to the experiment 
with the redox couple (Figure 2-5B). In both cases early kinetic intermediates were stable 
in the time scale of chromatography experiments and only partially precipitated outside 
the column overnight during storage. This is of particular interest when information about 
the size of kinetic intermediate is required for undertaking modelling and scale up. 
 
Figure 2-5. Effect of L-arginine using refolding buffer pH 8.1 and 9.5. (A) loading 
concentration of 20 mg/mL, (B) loading concentration of 40 mg/mL, and (C) loading 
concentration of 40 mg/mL without redox couple. The reduced pore accessibility due to 
presence of ʟ-arginine is evident from DTT elution volume.  
Another interesting observation of this work was faster elution of small molecules of urea 
and DTT when ʟ- arginine is added to the refolding buffer particularly at high protein 
concentrations. DTT elutes at 48.7±0.5 mL when no arginine is used regardless of protein 
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concentration (Figure 2-1A, B and Figure 2-4). However, its elution volume is influenced 
by protein concentration in the presence of ʟ- arginine eluting at 47±0.2 mL and 43.4±0.2 
mL for loading concentrations of 20 mg/mL and 40 mg/mL respectively (Figure 2-5A, B 
and C). Forrer et al. [30] demonstrated that the accessible porosity of an ion-exchange 
material is reduced at high protein concentrations, due to the increased protein binding to 
the resin surfaces. For the current study in SEC column, reduced pore accessibility for 
small molecules may be responsible for their faster elution due to formation of protein-
associated arginine clusters with larger sizes compared to protein monomer. The reduced 
transport properties for denaturing and reducing molecules achieved by the application of 
ʟ- arginine at high protein concentrations can prevent sudden removal of these molecules 
and protein aggregation [15,17], another mechanism by which ʟ- arginine can affect the 
on-column refolding yields at high concentrations. 
Adding NaCl to refolding buffer led to in-column precipitation, and in some cases, flow 
blockage. Flow blockage happened immediately after injection due to decreased 
solubility of unfolded lysozyme which is no longer protected by urea molecules after 
their immediate diffusion into the gel pores [18]. This is in contrast to lower loading 
concentrations in which similar concentration of NaCl is used and recommended to 
reduce the non-specific interactions in SEC columns [14]. As an alternative, optimized 
concentration of ʟ- arginine can be used to reduce the non-specific interactions with the 
gel and solid surfaces during purification and storage [21,31]. 
Using the subsequent optimized condition above 90% refolding yield was obtained for 
concentration as high as 40 mg/mL. The highest reported activity recovery for high 
concentration lysozyme (30.1 mg/mL) refolding in SEC is 80% [17] achieved by urea 
gradient SEC in which linear decrease of urea concentration along the column (8 M to 2 
M) prevents the aggregation. However, the challenge of column equilibration with a 
buffer containing 8 M urea is high pressure drop due to high viscosity of the buffer. 
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2.5 Conclusions 
The multi-variable investigation of lysozyme refolding in SEC at high concentrations 
carried out in this work revealed: (1) insignificant effect of protein concentration and 
refolding buffer pH on refolding yield at the presence of ʟ- arginine provided suitable 
redox couple is used; (2) reduced pore accessibility for small molecules of urea and DTT 
in SEC at the presence of ʟ- arginine and high protein concentrations; (3) early kinetic 
intermediates were identified during refolding with ʟ- arginine and found to be stable in 
the time scale of experiments in this work which allowed for size measurements in SEC. 
The possibility of working at high pH values for proteins with basic isoelectric points 
without self-association and aggregation problem due to the presence of ʟ- arginine might 
eliminate the need for addition of expensive redox couple. The reduced pore accessibility 
for denaturing and reducing molecules is an important factor in SEC refolding of protein 
as it prevents sudden removal of these agents and could be an additional mechanism by 
which ʟ- arginine additive prevents aggregation at high protein concentrations. These 
findings also provide more experimental evidence on proposed mechanism of arginine 
and protein interactions.  
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3 Oxidative Protein Refolding on Size Exclusion 
Chromatography at High Loading Concentrations: Fundamental 
Studies and Mathematical Modeling 
Abstract 
Size exclusion chromatography has been demonstrated as an effective method for 
refolding a variety of proteins. However, to date process development mainly relies on 
laboratory experimentation of individual factors. A robust model is essential for high-
throughput process screening and optimization of systems to provide higher productivity 
and refolding yield. In this work, a detailed kinetic scheme of oxidative refolding of a 
model protein (lysozyme) has been investigated to predict the refolding results in SEC. 
Non-reactive native, quenched and equilibrium studies were conducted to obtain the 
model parameters for the species formed during refolding of denatured/reduced 
lysozyme. The model was tested in various operating conditions, such as: protein loading 
concentration, injection volume, flow rate and composition of refolding buffer with and 
without the use of ʟ-arginine additive. An apparent two-state mechanism was found 
adequate to describe refolding of lysozyme on SEC for the operating condition tested in 
this work. Furthermore, using low concentration of ʟ-arginine combined with urea as 
common aggregation suppressor additives showed insignificant change in kinetics of 
refolding of lysozyme on SEC. However, addition of ʟ-arginine changed mass transfer 
properties of some of the species formed in refolding reaction which was considered in 
the model to accurately predict the result of refolding on SEC. 
3.1  Introduction 
The conventional method of protein refolding, namely batch dilution refolding, requires 
working at low protein concentrations in order to prevent aggregation, which in turn 
results in low productivity impeding high-throughput protein refolding and downstream 
processing for production of many bacterially expressed recombinant proteins [1]. Size 
Exclusion Chromatography (SEC)-based protein refolding addresses this issue to some 
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extent by facilitating gradual spatial isolation of protein molecules and unfolding agents, 
which can prevent aggregation and allow for application of higher protein loading 
concentrations and simultaneous purification compared with batch dilution refolding. For 
these reasons SEC has been widely used at lab scale for protein refolding in either batch 
or continuous mode using single or multiple column configurations (i.e. simulated 
moving bed) [1–9]. Existing work has also developed mathematical models for separation 
in SEC using various model proteins in their native forms [10,11]. For protein refolding 
in SEC (reaction-separation SEC), the refolding reaction is incorporated into the 
mathematical model as well as interactions of aggregating species in case they are formed 
under the operating conditions being studied  and the model parameters must be obtained 
for kinetic species formed during these reactions [5,12]. Development of an 
experimentally verified and robust model helps minimize the number of screening 
experiments for a broader range of operation condition and is essential for systematic 
process optimization. 
The mechanism of oxidative refolding reaction is commonly simplified to include only 
one intermediate involved in the rate limiting step based on dilution oxidative refolding 
kinetic data [13,14]. However, the ratio of kinetic constants of refolding steps is 
influenced by chemical composition of the environment [13,14] and this simplification 
may not be applicable in all cases. This is important in SEC as the refolding reaction is 
accompanied with protein size variation and a correct scheme of such variation along the 
column is necessary to accurately predict the elution profile of the protein. Furthermore, 
in case of aggregate(s) formation, the simplified mechanism is not able to capture the 
interactions of all intermediates that are prone to aggregation [5,14,15]. In this work, (1) a 
mathematical model for refolding of denatured/reduced lysozyme in SEC at high loading 
concentrations was developed to investigate a detailed reaction mechanism previously 
proposed for this protein which was selected as a model system due to importance of 
disulfide bond formation in considerable number of proteins [13]; (2) non-reactive native, 
quenched and equilibrium experiments were executed to find the model parameters for 
the final product and short-lived kinetic intermediates formed during unimolecular 
refolding reaction; (3) the model was tested by varying operating conditions, namely: 
protein loading concentration, injection volume, flow rate and composition of refolding 
 35 
 
buffer (with and without ʟ-arginine additive); and (4) the effect of low concentration (0.2 
M) of ʟ-arginine on mass transfer and kinetic parameters in SEC was studied. ʟ-arginine 
has been extensively studied and used to increase the refolding yield in batch dilution 
refolding by suppressing aggregation [16–19] and protein mass recovery in 
chromatography methods by decreasing non-specific interaction with the matrix [20,21]. 
In terms of kinetics of refolding, Reddy et al. [19] have reported insignificant change in 
apparent kinetic constant of oxidative refolding of lysozyme by batch dilution using 
guanidinium chloride and low concentration of ʟ-arginine (up to 0.5 M) to suppress 
aggregation. However in contrast to this, Chen et al. [18] observed a considerable 
decrease when both urea (2 M) and ʟ-arginine (0.5 M) were used in batch dilution 
refolding of recombinant human granulocyte colony-stimulating factor. Furthermore, 
Vagenende et al. [16] illustrated protein destabilization at the presence of low 
concentration of ʟ-arginine (<0.5 M) by differential scanning calorimetric method which 
might in turn result in reduced folding kinetics. To our knowledge there is no conclusive 
information available on the effect of ʟ-arginine on mass transfer properties of various 
refolding species and the kinetics of this reaction in SEC, making it a topic worthy of 
investigation. 
3.2 Modeling 
The protein refolding in size exclusion column was modeled using the transport-
dispersive and solid-film linear driving force models formulated from differential mass 
balances for solutes in the bulk-fluid phase and the particle-solid phase respectively [5]. 
The governing equations are 
𝜕𝐶𝑏,𝑖
𝜕𝑡
= 𝐷𝐿
𝜕2𝐶𝑏,𝑖
𝜕𝑥2
− 𝑢
𝜕𝐶𝑏,𝑖
𝜕𝑥
− 𝑃𝑘𝑜𝑣,𝑖(𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖) + 𝑟𝑏,𝑖 
(3-1) 
𝜕𝐶𝑠,𝑖
𝜕𝑡
= 𝑘𝑜𝑣(𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖) + 𝑟𝑠,𝑖 
(3-2) 
where 𝐶𝑏,𝑖 and 𝐶𝑠,𝑖 are the concentration of solute 𝑖 (unfolded, intermediates and native 
conformations) in bulk-fluid phase and solid phase respectively. 𝑡 is time, 𝑥 axial 
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distance along the column, 𝐷𝐿 axial dispersion coefficient, 𝑢 interstitial velocity, 𝑘𝑜𝑣,𝑖 
solute overall mass transfer coefficient, 𝑃 phase ratio, 𝐶𝑒𝑞𝑆,𝑖 the solid phase concentration 
in equilibrium with the bulk concentration. 𝑟𝑏,𝑖 and  𝑟𝑠,𝑖 are the net concentration change 
due to refolding reaction in bulk and solid phases with details presented in section 3.2.2. 
The solute solid phase concentration in equilibrium with the bulk concentration was 
treated as a linear equilibrium relationship with a fixed equilibrium constant [10]: 
𝐶𝑒𝑞𝑆,𝑖 = 𝐾𝑒𝑞,𝑖𝐶𝑏,𝑖 (3-3) 
where  𝐾𝑒𝑞,𝑖 is the equilibrium constant. 
The boundary and initial conditions used to solve equations (3-1) and (3-2) are: 
𝐶𝑏,𝑖(𝑡, 0
−) = {
𝐶𝑓,𝑖   0 < 𝑡 < 𝑡𝑝𝑢𝑙𝑠𝑒
0       𝑡 > 𝑡𝑝𝑢𝑙𝑠𝑒
 
(3-4a) 
𝜕𝐶𝑏,𝑖
𝜕𝑥
(𝑡, 𝐿𝐶) = 0 
(3-4b) 
𝐶𝑏,𝑖(0, 𝑥) = 0 (3-4c) 
𝐶𝑠,𝑖(0, 𝑥) = 0 (3-4d) 
where  𝐶𝑓,𝑖 is solute concentration in feed, 𝑡𝑝𝑢𝑙𝑠𝑒 is the duration of sample injection, and 
𝐿𝐶 is the column length. The assumption that the sample is introduced into the column as 
a rectangular pulse of length 𝑡𝑝𝑢𝑙𝑠𝑒 may not be valid in most practical applications. 
However, as the injection time is very small compared to retention time, such 
simplification still seems to be applicable [22]. 
To solve the above system, the first and second spatial derivatives were discretized using 
fourth-order finite difference equations except for boundary points for which second 
order forward and backward finite difference approximations were used. The resulting 
method of lines system of ODEs was solved numerically in MATLAB by ode15s solver. 
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3.2.1 Determination of Model Parameters 
The axial dispersion coefficient was calculated based on the definition of the Peclet 
number, which was estimated using the correlation of Chung and Wen for small Reynold 
numbers as follows [5] 
𝐷𝐿 =
𝑢𝐿𝑐
𝑃𝑒
 
(3-5a) 
𝑃𝑒 =
0.1𝐿𝑐
𝑅𝑝𝜀𝑏
 
(3-5b) 
where 𝑅𝑝 is particle radius and 𝜀𝑏 is bed void volume fraction which was measured using 
thyroglobulin from bovine thyroid as a test probe 
𝜀𝑏 =
𝑉0
𝑉𝑐
 
(3-6) 
where 𝑉0 and 𝑉𝑐 are the elution volume of thyroglobulin from bovine thyroid and column 
volume respectively, correcting by subtracting the system volume such as tubing and 
valves. The phase ratio (void to non-void volume) is 
𝑃 =
1 − 𝜀𝑏
𝜀𝑏
 
(3-7) 
The mass transfer and equilibrium constants (𝑘𝑜𝑣,𝑖 and 𝐾𝑒𝑞,𝑖) were found by minimization 
of the deviation of measured concentration vs. calculated in a least squares sense using 
fmincon function in MATLAB with an additional constraint for recovery (𝑅𝑏,𝑖 ≤1) which 
was defined as 
𝑓(𝑥) = ∑(𝐶𝑏,𝑖
𝑒𝑥𝑝,𝑗 − 𝐶𝑏,𝑖
𝑓𝑖𝑡,𝑗(𝑥))2
𝑗=𝑛
𝑗=1
 
(3-8) 
𝑅𝑏,𝑖=
𝑀𝑖
𝐶𝑓,𝑖 𝑉𝑝𝑢𝑙𝑠𝑒
 
(3-9) 
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where 𝑥 is a vector of mass transfer and equilibrium constants, 𝐶𝑏,𝑖
𝑒𝑥𝑝 
 the vector of 
experimental solute concentration at the column outlet, 𝑛 the number of elements in 
concentration vector,  𝑀𝑖  sum of mass of solute collected in fractions and 𝑉𝑝𝑢𝑙𝑠𝑒 is 
injection volume.The initial guesses for these parameters were estimated as follows: 
𝐾𝑒𝑞,𝑖 = 𝑘𝑠𝑒𝑐,𝑖 =
𝑉𝑒,𝑖− 𝑉0
𝑉𝑡 − 𝑉0
 
(3-10) 
where 𝑘𝑠𝑒𝑐,𝑖 is the average distribution coefficient (size exclusion capacity) of solute, 
𝑉𝑒,𝑖 is its elution volume and 𝑉𝑡 is total porosity volume of the column determined by 
pulse injection of acetone.  
Freydell et al. [5] have provided a complete list of references which report correlations 
for calculation of protein free diffusivity, pore diffusivity and film mass transfer 
coefficient in order to calculate 𝑘𝑜𝑣 .The hydrodynamic radius of the solute is necessary 
to estimate the above parameters. In the same paper, they proved the adequacy of 
extended-Ogston model to correlate average distribution coefficient to the hydrodynamic 
radius of proteins in two different gel materials namely Superdex75 and Sephaseryl 100. 
In this work, the same model was used to construct a calibration curve for the size 
exclusion column and find the molecular size of various species.  This method is an 
efficient way to measure molecular size of kinetic species involved in a refolding 
reaction. 
Finally, the kinetic constants in the rate terms were determined by minimizing 𝑓(𝑥)for 
recovered native protein elution profiles with constrain of refolding yield (𝑌𝑏≤1) which 
was defined as 
𝑌𝑏 =
𝑀𝑛𝑎𝑡𝑖𝑣𝑒
𝐶𝑓,𝑈 𝑉𝑝𝑢𝑙𝑠𝑒
 
(3-11) 
where 𝑀𝑛𝑎𝑡𝑖𝑣𝑒 is sum of native protein mass collected in fractions and 𝐶𝑓,𝑈 is unfolded 
lysozyme concentration in feed. 
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3.2.2 Reaction Scheme 
An adequate kinetic scheme is required to predict the on-column refolding results. 
Deviation of lysozyme refolding, in low denaturant environment (e.g up to 1 M urea), 
from two-state kinetics behaviour (cooperative refolding) is evident and its refolding 
involves at least one intermediate both for denatured and denatured/reduced forms of the 
protein [13,23–26]. However, lysozyme refolding kinetic data has been interpreted in 
many different ways and more than one “pathway model” can fit the experimental results 
[23]. Some research work suggests the existence of parallel refolding pathways which is 
justified by heterogeneity of unfolded state and includes a fast direct refolding from 
unfolded to native state and a slow refolding through formation of intermediates. 
However, only small fractions of molecules seem to follow the direct pathway [13,24,25]. 
Nevertheless, the refolding of reduced and denatured lysozyme has been successfully 
modeled using a single dominant reaction pathway in batch and fed batch refolding 
[14,15]. The reaction mechanism is shown in Figure 3-1; it is suggested that early 
intermediates with only a fraction of disulfide bridges are rapidly formed during 
“collapse process” followed by formation of native-like intermediates and a slow 
conversion of these intermediates to the native state [13]. 
 
Figure 3-1. Lysozyme refolding kinetic scheme, U: unfolded protein, Ie: early 
intermediates, IN: native-like intermediates and N: native protein. 
According to this scheme the reaction rates for both bulk (𝑟𝑏,𝑖) and solid (𝑟𝑠,𝑖) phases in 
equations (3-1) and (3-2) are as following 
𝑟𝐼𝑒 = −𝑘1𝐶𝐼𝑒 (3-12a) 
𝑟𝐼𝑁 = 𝑘1𝐶𝐼𝑒 − 𝑘2𝐶𝐼𝑁 (3-12b) 
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𝑟𝑁 = 𝑘2𝐶𝐼𝑁 (3-12c) 
Furthermore, formation of misfolded lysozyme with non-native contact, presumably 
incorrect disulfide bridges, has also been previously observed [8,27] and therefore might 
be included in the reaction mechanism. However, in this work very small fraction of 
misfolded protein was observed over the course of experiments. The misfolded species 
also slowly convert to native state [27] and therefore their formation was neglected for 
the purposes of this work. 
3.3 Materials and Methods 
3.3.1 Chemicals 
Reagent grade Bovine Serum Albumin (BSA), ʟ-arginine and urea, Ethylene Diamine 
Tetra Acetic acid (EDTA), lysozyme from chicken egg white, trizma® base (Tris-base), 
ʟ-cysteine, ʟ-cystine, BioUltradithiothreitol (DTT) solution, Micrococcus lysodeikticus, 
potassium phosphate monobasic,  BioXtra sodium chloride, Trifluoric acetic acid (TFA) 
reagent plus grade and acetonitrile 0.1% TFA were purchased from Sigma-Aldrich, 
Canada. Red 660™ protein assay reagent was purchased from G-Biosciences, USA. 
Superdex™75pg resin (34 µm average particle size) was purchased from GE Healthcare, 
Canada. 
3.3.2 Analytical Methods 
3.3.2.1 UV Absorption 
Samples of native protein were prepared in 0.1 M phosphate solution buffered at pH 7 in 
order to determine the purity and lysozyme percentage of powder. The concentration of 
native lysozyme was determined with ultraviolet (UV) absorption spectroscopy 
(Shimadzu UV-3600) using extinction coefficient of 2.63 ml/mg/cm [27]. The 
concentration of native lysozyme standards prepared in refolding buffer was determined 
accordingly. The concentration of native protein in fractions collected during non-
reactive native experiments was determined by using a Tecan M200 plate reader.  
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BSA standards were prepared in refolding buffer using 96% BSA powder and 
concentration of BSA in collected fractions were determined by comparing the fractions 
and standard protein samples UV absorbances using the plate reader. 
3.3.2.2 Native Lysozyme Concentration 
A Vydac 214MS C4 column (5 µm, 250 x 4.6 mm) was used on an Agilent HPLC system 
to separate native protein from other conformations and determine its concentration in 
collected samples during reactive experiments. A linear acetonitrile-water gradient with 
0.1% (v/v) TFA starting at 25% acetonitrile increasing at 2.3%/min was used to elute the 
protein in 10min. The total solvent flow rate, column temperature and injection volume 
were set at 1 mL/min, 20 ºC and 50 µL respectively.   
3.3.2.3 Enzymatic Activity and Total Protein Concentration 
The enzymatic activity of fractions was compared with activity of standard protein 
samples. The enzymatic activity of samples and standards were measured by recording 
the linear decrease of cell suspension absorbance (0.3 mg/mL Micrococcus- 
lysodeikticusin 0.1 M phosphate buffer, pH 7) at 450 nm after mixing using a 
microtiterplate reader after shaking for 40s [8].  
The total protein concentrations in samples were determined using Red 660™ protein 
assay in which 10 µl protein samples was transferred to each well, 150 µL of reagent was 
added and mixed (6.5 mm circular shaker)using the plate reader, and absorbance of the 
mixture at 660 nm was measured after 5 min. The total protein concentrations were 
calculated by comparing the fraction and standard protein sample absorbance.   
3.3.3 Feed Preparation 
Unfolding buffer (0.1 M Tris-base, 1 mM EDTA, 6 M urea and 32 mM DTT, pH 8.1) 
was used to prepare various concentrations of denatured/reduced lysozyme (2-20 
mg/mL). The excess of DTT was used to assure complete reduction of disulfide bridges. 
The sample was incubated for 2 h at 37 °C [8] and loss of native structure was confirmed 
by RP-HPLC analysis afterwards.  
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3.3.4 Experimental Set up 
A XK16/40 column (GE healthcare, Canada) was packed with Superdex™75pg resin 
(column volume ~54 mL). The packed column was installed on ÄKTA purifier 100 
controlled by UNICORN 5.31 software and equipped with online pH probe, UV detector 
and conductivity cell. The fractionation kit allows the collection of samples at desired 
volumes. Acetone pulse injection (2% (v/v)) was used to test the packing quality by 
comparing the peak symmetry and number of theoretical plates per length of column with 
manufacturer recommended criteria. Column void volume is commonly determined by 
blue dextran; however it was observed that blue dextran binds to superdex75pg and does 
not elute from the column despite using recommended concentration of salt in the mobile 
phase. Therefore, thyroglobulin from bovine thyroid (669 kDa) which is completely 
excluded from the macropores of Superdex75pg (fraction range of 3-70 kDa) was 
injected on the column to measure the void fraction.   
3.3.5 SEC Non-reactive Experiments 
Various concentrations and volumes of native lysozyme was injected on the column 
equilibrated with 2 column volumes (CV) of a refolding buffer identical to buffer used 
for reactive experiments. The protein was eluted using the same buffer and 1mL/min flow 
rate while 0.5 mL fractions were collected for UV absorbance analysis to determine the 
native protein concentration in each fraction.  The model parameters for native species 
were fitted against these experimental results. Refolding buffer A  was composed of 0.1 
M Tris, 1 mM EDTA, 2 M urea, 0.2M ʟ-arginine, 3 mM cysteine, 0.3 mM cysteine 
buffered at pH 8.1 while in refolding buffer B, ʟ-arginine is replaced by 0.1 M NaCl to 
investigate the implication of removing ʟ-arginine in terms of mass transfer parameters 
and kinetics of refolding. The addition of NaCl was necessary to prevent non-specific 
interactions with the column [7,20]. 
The redox couple was then removed from buffer A to quench the refolding at early 
intermediates [28,29] and fit the model parameters for these species. Fractions of 0.5 mL 
were collected and analyzed using total protein assay. 
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Native-like intermediates of lysozyme have been recovered in batch experiments by acid-
quenching and HPLC separation of samples recovered at later stages of refolding [13]. 
Alternatively, it may be possible to gain information on the structure of kinetically short-
lived intermediates by performing equilibrium experiments [23]. In the case of lysozyme, 
the characteristics of kinetic native-like intermediates formed in refolding of denatured 
and denature-reduced hen egg lysozyme are very similar [13] and equilibrium 
intermediate has been detected in unfolding experiments using urea where native-like 
intermediates showed the highest population at 4M urea [30]. Therefore equilibrium 
studies were performed to find the model parameters for native-like lysozyme. The 
column was equilibrated with 2 CVs of buffer C (0.1 M Tris, 1 mM EDTA, 4 M urea, 0.2 
M ʟ-arginine) and the same buffer was used to dissolve lysozyme which was incubated 
over night at 37 ºC. The protein was eluted using 0.5mL/min flow rate to avoid high 
pressure drop due to the high concentration of urea present in the equilibrium buffer C. 
Fractions of 0.5 mL were collected and analysed using total protein assay.  
3.3.6 SEC Refolding- Reactive Experiments  
The column was equilibrated with 2 CVs of the refolding buffer A and various volumes 
(0.5 and 1 mL) and concentrations (5, 10 and 20 mg/mL) of denatured/reduced lysozyme 
was injected and eluted using the same buffer and flow rate of 1mL/min with exception 
of one run where 0.5mL/min flow rate was used. The above loading concentration range 
was selected based on previous studies which demonstrated no aggregation formation 
within this range [31]. Fractions of 1mL were collected and analyzed using RP-HPLC to 
determine the concentration of correctly refolded protein. The enzymatic activity and 
total protein analysis were also carried out for some reactive experiments to gain more 
information on characteristics of recovered species. 
For reactive experiments without ʟ-arginine, the column was equilibrated with 2 CVs of 
the refolding buffer B and various volumes (0.5, 1 and 2 mL) of 2 and 5 mg/mL 
denatured/reduced lysozyme were injected and eluted with the same buffer. Low loading 
concentrations were selected to assure no aggregates were formed.  Fractions of 1mL 
were again collected and analysed using RP-HPLC. 
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All the buffers were prepared fresh using ultra-pure water (Barnstead easy-pure RODI 
equipped with 0.2 µm filter, Fisher Scientific), filtered again with a 0.2 µm membrane 
and de-gassed prior to use. The column was washed with 2 CVs de-ionized water after 
final elution. 
3.4 Results and Discussion 
3.4.1 Non-reactive Experiments 
The average experimental distribution coefficient (𝑘𝑠𝑒𝑐,𝑁) and fitted values for the 
equilibrium solid phase concentration (𝐾𝑒𝑞,𝑁) and the overall mass transfer coefficient 
(𝑘𝑜𝑣,𝑁) of the native protein using buffers A and B are reported in Table 3-1. In both 
cases, 𝐾𝑒𝑞,𝑁 is less than 𝑘𝑠𝑒𝑐,𝑁. Figure 3-2 shows the satisfactory agreement between 
experimental and predicted results for native protein elution profiles. Reduced average 
distribution coefficient, equilibrium solid phase concentration and overall mass transfer 
coefficient when buffer A is used compared to buffer B, indicated a larger apparent 
radius of native protein in the presence of ʟ-arginine. Vagenende et al. reported similar 
results and explained this observation based on formation of “dynamic arginine-protein 
associated clusters” extended from the surface of the protein [16]. As discussed earlier, 
the apparent radius was extrapolated using column calibration curve (Figure 3-3) based 
on extended-Ogston model. The lysozyme hydrodynamic radius measured in this work is 
larger than some reported values [30] as lysozyme swells in the presence of urea but is 
consistent with results reported for urea [32]. 
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Table 3-1. Average distribution coefficient, fitted model parameters and apparent radius 
of kinetic species formed during lysozyme refolding. Solute 𝒊 is native lysozyme for first 
and second row early and native-like intermediates for third and fourth row respectively. 
Buffer 𝑘𝑠𝑒𝑐,𝑖 (-) 𝐾𝑒𝑞,𝑖 (-) 𝑘𝑜𝑣,𝑖 (min
-1
) Apparent rh 
(nm) 
A 0.55±0.01 0.44±0.003 17.29±1.99 1.8 
B 0.58±0.01 0.49±0.002 21.61±1.55 1.7 
A and B 0.08±0.01 0.08±0.004 2.69±0.45 3.5 
C 0.47± 0.004 0.39±0.001 16.19±0.22 2 
 
 
Figure 3-2. Experimental vs. predicted native protein elution profiles using buffer A (top 
row) and B (bottom row). 
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Figure 3-3. Size exclusion column calibration curve based on extended-Ogston model. 
Quenched experiments were carried out to determine model parameters. Figure 3-4A 
shows the agreement between experimental and predicted elution profiles of early 
intermediates using fitted (least squares) values of 0.24±0.002 and 14.37±1.97 min
-1
 
respectively. However, early intermediates under quenching conditions showed a higher 
elution volume compared with reactive experiments (Figure 3-6A). This may be due to 
increased non-specific interaction at higher concentration of early intermediates with the 
gel in quenched experiments compared to short-lived early intermediates in reactive 
experiments.  However, this is in contrast with that presented in our previous work [31] 
where the same elution volumes were observed and suggest that Superdex75pg surface 
properties changes over time well before expiry of the gel as indicated by manufacturer 
(~ 2 years ). Binding of blue dextran to the gel during void volume measurements (as 
mentioned before) was another indication of such change over time. The recovered 
protein still did not show any enzymatic activity and the florescence intensity was higher 
than native protein (data not shown). Since elution position of early intermediates was 
seemingly affected by interactions with the gel matrix during quenched experiments, the 
model parameters were fitted for BSA protein (66.5 kDa) elution profiles and  used as a 
model compound (Figure 3-4B). BSA was used because it showed the same elution 
volume as early intermediates in reactive experiments suggesting the same extent of 
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exclusion within fraction range of the gel. As shown in Figure 4B, the elution volume of 
BSA was not influenced by the type of refolding buffer and the same model parameters 
were fitted for when buffer A or B were used as reported in Table 3-1. 
 
Figure 3-4. (A) Experimental vs. predicted early intermediate elution profiles using 
buffer A without redox couple to quench the reaction at early intermediates (B) 
Experimental vs. predicted BSA elution profile used as a model compound to find model 
parameters for early intermediates. 
Figure 3-5 shows the elution profiles of lysozyme equilibrated in refolding buffer C. As 
described in section 3.3.5 the model parameters and size information for native-like 
intermediate were calculated using equilibrium studies (summarized in Table 3-1). 
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Figure 3-5. Experimental vs. predicted elution profiles of lysozyme equilibrated in 
buffer-C. 
3.4.2 Reactive Experiments 
Three protein conformations were recovered in reactive experiments using refolding 
buffer A, as shown in Figure 3-6A.  
 
Figure 3-6. (A) Chromatogram of refolding of lysozyme using refolding buffer A (L=10 
mg/mL, Vpulse=1 mL) and (B) Chromatogram of protein pool obtained from reactive 
experiment of (A). 
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The first peak is associated with early intermediates with no enzymatic activity. The 
second and third peaks showed similar enzymatic activity based on measurement with 
enzymatic activity and total protein assays. However, considering the elution profile of 
the recovered protein pool (Figure 3-6B), it is obvious that only one peak corresponds to 
native lysozyme eluting at the same volume as non-reactive native protein injections and 
the peak eluting before that was characterized as misfolded protein. It can be observed on 
Figure 3-6A that fractions containing early intermediates also contain misfolded protein 
(overlapping peaks) and quantification of either early intermediate or misfolded was not 
possible by HPLC analysis due to unavailability of standards for these species. The 
difference between total protein concentration and native protein is the summation of 
these two species and they cannot be quantified individually. This highlights the need for 
conducting quenched experiments or use of a model compound such as BSA to find 
model parameters to provide estimates for early intermediates. 
A simplified reaction scheme considering native-like intermediate to native protein as the 
rate-limiting step was initially used to find the reaction rate constants and simulate the 
results of on-column refolding in this work. However, as shown in Figure 3-7 it was 
observed that this mechanism does not produce a satisfactory agreement between 
experimental and predicted values due to exclusion of early collapsed to native-like 
intermediate step from refolding reaction.  
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Figure 3-7. Experimental vs. predicted native protein elution profiles recovered during 
reactive experiments using a simplified reaction scheme from native like intermediate to 
native lysozyme. 
On the other hand, an apparent two-state refolding representation of the reaction 
mechanism including early collapsed intermediates to native protein showed a 
satisfactory fit as shown in Figure 3-8. For one case of low flow rate (0.5 mL/min), the 
same mass transfer parameters as higher flow rate (1 mL/min) were used because 
estimated film and pore mass transfer resistances (determined using correlations) 
revealed the pore resistance as the major resistance component and this value is 
independent of velocity [10]. 
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Figure 3-8. Experimental vs. predicted native protein elution profiles recovered during 
reactive experiments where an apparent two- state representation of reaction mechanism 
was used. 
The apparent reaction rate constant was found to be 0.08±0.01 min
-1
 and 0.1±0.01 min
-1
 
for refolding with buffer A and B respectively, indicating that the low concentration of ʟ-
arginine utilized in this work prevented aggregation without compromising the speed of 
the reaction (values are identical at 95% statistical significance). It should be noted that 
the disagreement between experimental and model prediction at the tail of the peak is due 
to non-specific interactions with the gel, which were not accounted for in the model. 
From these results it is evident that disappearance of the early intermediates is not 
immediate. Gradual removal of denaturing and reducing agents in SEC and the chemical 
composition used in this work may explain this behavior of the protein. For example, 
higher local concentration of chaotropic molecules such as urea has shown reduced 
apparent kinetics [33]. However, higher local concentration of such molecules and their 
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gradual removal protects early intermediate species against aggregation resulting in 
advantage of SEC over dilution refolding. In addition, carryover of excess concentration 
of reducing agent used in feed preparation can lead to suboptimum concentration ratio of 
redox couple and slow reformation of native disulfide bridges [8]. 
One should bear in mind that although the assumption of constant kinetics was proved 
applicable in this work, it may not be valid in higher loading volumes and reaction rate 
term may be more accurately determined via local concentrations of denaturing and 
reducing agents [6,33]. For example the full potential of SEC for protein refolding is 
realized in the application of continuous processing configurations such as simulated 
moving bed which normally results in less dilution and higher local concentrations [6]. 
Similarly, although no aggregates were formed at concentrations studied in this work the 
possibility of aggregation must be considered at higher loading volumes and local 
concentrations of protein. 
3.5 Conclusion 
The fundamental studies of oxidative protein refolding in SEC in this work showed: 1) an 
apparent two-state refolding mechanism adequately describes the refolding of model 
protein lysozyme on SEC highlighting the importance of chemical composition of the 
refolding environment and the rate by which this composition changes on kinetics of 
refolding; 2) different methods that can be used to find characteristic information about 
species involved in a refolding reaction such as quenched and equilibrium experiments 
and use of model compounds which is essential for model development and simulation of 
protein refolding on SEC; 3) examination of effect of ʟ-arginine on characteristics of 
protein conformations showed higher apparent radius of the native lysozyme and no 
apparent change on larger protein conformations such as early intermediates and BSA at 
the presence of this additive; 4) low concentration of ʟ-arginine used in this work (0.2 M) 
combined with 2 M urea showed insignificant effect on the rate of refolding reaction. 
This is of particular interest due to extensive application of these compounds as 
aggregation suppressor additives. 
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The same model can be extended to higher loading volumes or protein concentrations 
provided that the effect of local concentration of denaturing and reducing agents and local 
protein concentration on kinetics of refolding and aggregation are incorporated into the 
model. 
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4 Oxidative Protein Refolding on Size Exclusion 
Chromatography: From Batch Single-column to Multi-column 
Counter-current Continuous Processing 
Abstract 
Recently size exclusion chromatography (SEC) used in multi-column continuous 
simulated moving bed (SMB) configurations (hereinafter SMB-SEC) has been 
investigated for protein refolding at industrial scale. This is due to several advantages 
offered by SMB configurations particularly when process parameters are thoroughly 
screened and optimized. A robust mathematical model is essential for high-throughput 
process screening and optimization. In this work, a previously investigated single-column 
mathematical model was modified to extend its applicability for protein oxidative 
refolding/aggregation predictions in SMB-SEC. The model considers a wider loading 
concentration range of the model protein (lysozyme) on SEC. The potential influences of 
high concentrations of chaotropic reagents on kinetic and thermodynamic model 
parameters have been discussed based on previous experimental results and their 
predicted local concentrations through the SMB-SEC columns and at the product steam. 
It was observed that aggregation occurs when local protein concentration exceeds a 
critical concentration. No urea recovery at the product stream indicated that the refolding 
reaction will continue off-column to recover the native- protein product. Therefore, it is 
suggested that the developed model is tested against experimental results for total 
solubilized protein (early intermediates and native conformations) and process 
performance indicators are defined based on solubilized protein. 
4.1 Introduction 
Despite the advances made to date for expression of protein-therapeutics using E-coli [1], 
existing technologies to recover active and high-purity product still incur significant costs 
due to low product concentration and high buffer consumption during conventional batch 
dilution refolding process resulting in low volumetric productivity [2]. As an alternative 
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due to the gradual separation of unfolded protein molecules from denaturing and reducing 
agents and their separation from solubilized aggregates in SEC, which in turn results in 
high refolding yield and purity, SEC has been widely used at lab scale [3–9]. However, 
this method in form of single-column batch processing may not enhance the 
aforementioned process performance indicators for industrial scale production of E-Coli-
based protein-therapeutics. On the other hand, a multi-column continuous simulated 
moving bed system offers several advantages compared to single-column batch operation 
including increased productivity per unit mass of solid phase, lower solvent consumption, 
and less diluted products. This configuration consists of a set of chromatographic 
columns connected in series and is operated in continuous mode; the inlet/outlet lines are 
periodically shifted synchronously in the direction of liquid-phase flow to mimic 
countercurrent movement between a liquid-solvent and a solid phase. Multi-column 
continuous simulated moving bed is a well-established process for intensified difficult 
separations of small molecules and fine products e.g. separation of enantiomers [10,11]. 
However, its application for protein refolding and separation has recently attracted the 
attention of researchers [3–5,7]. For example, Freydell et al. [5] have reported a 35 times 
increase in productivity and 1/10 solvent consumption when a SMB-SEC was used for 
refolding of a model fusion protein compared to single-column processing.  
Since many parameters are involved in operating a SMB-SEC (i.e. internal and external 
flow rates, switching time and feed concentration) systematic optimization studies are 
required to exploit the full potential of this system. A mathematical model is a pre-
requisite for screening of process parameters and optimization. Freydell et al. [5] used a 
previously investigated single-column model in order to predict refolding/aggregation of 
a fusion protein in a four-zone SMB-SEC configuration comprised of multiple columns 
connected in series. They observed considerable discrepancy between model predictions 
and experimental results. For instance, the refolding yield was over-predicted by a factor 
of three. As discussed in the same work, this disagreement can be related to lower 
dilution factor in SMB-SEC compared to a batch single-column refolding resulting in 
higher local concentration of chaotropic agents (urea and DTT). And, in order to improve 
the SMB-SEC model- predictions in terms of native protein recovery the influence of 
local concentration of urea and DTT on model parameters should be considered.  
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The effect of lower dilution factor is twofold, as in addition to higher local concentrations 
of chaotropic reagents it also results in higher local protein concentration compared to a 
batch single-column refolding. Higher local protein concentration may additionally result 
in different reaction schemes. For example if for a single-column refolding experiment no 
aggregation was observed there would still remain the possibility of aggregation in SMB-
SEC at the same protein loading concentrations.  
In this work, (1) a previously experimentally verified single-column model was modified 
to expand its applicability for prediction of oxidative protein refolding/aggregation on 
SMB-SEC by considering a wider protein loading concentration range and the additional 
model parameters resulting from this modification were determined experimentally; (2) 
the sensitivity of refolding kinetics and possible complexity arising from reducing agent 
(DTT) carry-over have been discussed and DTT-free refolding was investigated and 
compared to previous studies with DTT carry-over; (3) the denaturing reagent (urea) 
mass transfer parameters were measured experimentally and used to predict the 
concentration of urea through SMB-SEC columns and at the product outlet under the 
current operation conditions; (4) the suitability of the developed model for process 
optimization was investigated; and (5) the effect of SMB-SEC operating parameters 
namely loading concentration and switching time on process performance indicators were 
predicted and the results were compared to single-column oxidative refolding of 
lysozyme.  
4.2 Mathematical Model and Theory 
4.2.1 Column Model 
The protein refolding in size exclusion column was modeled using dispersive transport in 
the bulk with a film linear mass transfer resistance between particle-solid and bulk-liquid 
phases. The formulated differential mass balances for solutes in the bulk and the solid 
phases are [6]. 
𝜕𝐶𝑏,𝑖
𝜕𝑡
= 𝐷𝐿
𝜕2𝐶𝑏,𝑖
𝜕𝑥2
− 𝑢
𝜕𝐶𝑏,𝑖
𝜕𝑥
− 𝑃𝑘𝑜𝑣,𝑖(𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖) + 𝑟𝑏,𝑖 
(4-1) 
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𝜕𝐶𝑠,𝑖
𝜕𝑡
= 𝑘𝑜𝑣(𝐶𝑒𝑞𝑆,𝑖 − 𝐶𝑠,𝑖) + 𝑟𝑠,𝑖 
(4-2) 
where 𝐶𝑏,𝑖 and 𝐶𝑠,𝑖 are the concentration of solute 𝑖 (unfolded, intermediates and native 
conformations) in bulk and solid phase respectively. In equations (4-1) and (4-2), 
𝑡 represents time, 𝑥 axial distance along the column, 𝐷𝐿 axial dispersion coefficient, 𝑢 
interstitial velocity, 𝑘𝑜𝑣,𝑖 solute overall mass transfer coefficient, 𝑃 phase ratio, 𝐶𝑒𝑞𝑆,𝑖 the 
solid phase concentration in equilibrium with the bulk concentration. 𝑟𝑏,𝑖  and  𝑟𝑠,𝑖 are the 
net concentration change due to refolding and aggregation reactions in bulk and solid 
phases, which are described further in section 4.2.3.  
The solute solid phase concentration in equilibrium with the bulk concentration was 
treated as a linear equilibrium relationship with a fixed equilibrium constant [12]:  
𝐶𝑒𝑞𝑆,𝑖 = 𝐾𝑒𝑞,𝑖𝐶𝑏,𝑖 (4-3) 
where 𝐾𝑒𝑞,𝑖 is the equilibrium constant. 
The boundary and initial conditions used to solve equations (4-1) and (4-2) are: 
𝐶𝑏,𝑖(𝑡, 0
−) = {
𝐶𝑓,𝑖   0 < 𝑡 < 𝑡𝑝𝑢𝑙𝑠𝑒
0       𝑡 > 𝑡𝑝𝑢𝑙𝑠𝑒
 
(4-4a) 
𝜕𝐶𝑏,𝑖
𝜕𝑥
(𝑡, 𝐿𝐶) = 0 
(4-4b) 
𝐶𝑏,𝑖(0, 𝑥) = 0 (4-4c) 
𝐶𝑠,𝑖(0, 𝑥) = 0 (4-4d) 
where 𝐶𝑓,𝑖 is solute concentration in feed, 𝑡𝑝𝑢𝑙𝑠𝑒 is the duration of sample injection, and 
𝐿𝐶 is the column length. The assumption that the sample is introduced into the column as 
a rectangular pulse of length 𝑡𝑝𝑢𝑙𝑠𝑒 was initially used as it has proven applicable in some 
cases [6,13]. However, the experimental injection profile was later introduced by a 
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Gaussian distribution function to further improve the accuracy of the model parameters 
and prediction results. 
To solve the 𝐶𝑏,𝑖 and 𝐶𝑠,𝑖  along 𝑥 at different times, the first and second spatial 
derivatives were discretized as fourth-order central finite difference equations except for 
boundary points where second order forward and backward finite difference 
approximations were used. The resulting system of ODEs in time (method of lines) was 
solved numerically in MATLAB. 
4.2.2 SMB-SEC Model 
The selected design parameters of SBM-SEC model (e.g. number of columns in each 
zone and column dimensions) in this work were identical to the system used by Freydell 
et al. [5]. Figure 4-1 is a schematic representation of their system. Each zone comprises 
of two columns connected in series and as shown on the same figure an open loop system 
was used.  
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Figure 4-1. Schematic representation of a four-zone SMB-SEC: QD, QEx, QRa, QF and QW 
are buffer, extract, raffinate, feed and waste flow rates respectively. Qj is internal flow 
rate in zone j: 1-4) 
The dimension of each column is 1 cm i.d and packed bed height of ~8 cm.  Each column 
was modeled with the same approach as for single column except that boundary 
conditions are taken as periodic. The changing boundary condition is simulated by 
hypothetical movement of solid (direction shown on Figure 4-1) or more accurately 
switching columns’ positions after each switching time. The boundary condition for each 
node is then:  
𝐶𝑏,𝑖 (𝑡, 𝐿1
+) = 𝐶𝐷,𝑖 (4-5a) 
𝐶𝑏,𝑖 (𝑡, 𝐿2
+) = 𝐶𝑏,𝑖 (𝑡, 𝐿1
−) (4-5b) 
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𝐶𝑏,𝑖 (𝑡, 𝐿3
+) =
𝑄𝐹𝐶𝑓,𝑖 + 𝑄2𝐶𝑏,𝑖 (𝑡, 𝐿2
−)
𝑄3
 
(4-5c) 
𝐶𝑏,𝑖 (𝑡, 𝐿4
+) = 𝐶𝑏,𝑖 (𝑡, 𝐿3
−) (4-5d) 
where 𝐶𝐷,𝑖 is the concentration of solute 𝑖 in the refolding buffer.   
4.2.3 Reaction Scheme  
The refolding of reduced/denatured lysozyme has been successfully modeled using a 
single dominant reaction pathway in batch and fed batch refolding [14,15]. The reaction 
mechanism is shown in Figure 4-2.  
 
Figure 4-2. Lysozyme refolding and aggregation kinetic scheme, U: unfolded protein Ie: 
early intermediates,  IN :native-like intermediates,  N: native protein, An : aggregates (n: 2 
and 3). 
It is suggested that early intermediates with only a small fraction of disulfide bridges are 
rapidly formed during “collapse process”, followed by formation of native-like 
intermediates and a slow conversion of these intermediates to native state [16]. Since 
early intermediates are more susceptible to aggregation compared to native-like 
intermediates, aggregation is considered the result of early intermediate species 
association via sequential polymerization mechanism [6,14,15]. In our previous work, 
lysozyme refolding on SEC could be well described by an apparent two state mechanism 
involving early intermediates and native lysozyme [17]. Furthermore when lysozyme was 
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refolded without ʟ-arginine additive, only one size of solubilized aggregates was 
recovered [18], therefore it was assumed that only one size of aggregate is also formed in 
the presence of ʟ -arginine and aggregation was then regarded as a second order reaction. 
According to this simplified scheme the reaction rates for bulk (𝑟𝑏,𝑖) and solid (𝑟𝑠,𝑖) 
phases in equations (4-1) and (4-2) are as following 
𝑟𝐼𝑒 = −𝑘𝑎𝑝𝑝𝐶𝐼𝑒 − 2 𝑘𝑎(𝐶𝐼𝑒)
2 (4-6a) 
𝑟𝐼𝑁 = 𝑘𝑎𝑝𝑝𝐶𝐼𝑒  (4-6b) 
𝑟𝐴2 = 𝑘𝑎(𝐶𝐼𝑒)
2 (4-6c) 
where  𝑘𝑎𝑝𝑝 and  𝑘𝑎 are apparent refolding and aggregation kinetic constants 
respectively. 
Aggregation occurs at higher local concentrations which might be purely due to increased 
aggregation kinetics competing with refolding reaction or surpassing early refolding 
kinetic species solubility [19]. In the former case, the thermodynamic condition for 
aggregation formation is always satisfied while for the latter there is a critical 
concentration above which aggregates are formed. Elution profiles of refolded native 
protein for lysozyme refolding on SEC for a wide protein loading concentration range (5-
50mg/mL) are examined in this work to investigate both case scenarios, assessed through 
inclusion of these effects in the model through an aggregation kinetic constant (𝑘𝑎) and 
early intermediate solubility (𝐶𝑠). If a critical concentration is required to describe the 
results of refolding/aggregating on SEC, the aggregation rate is modelled as following 
𝑟𝐴2 = {
𝑘𝑎(𝐶𝐼𝑒)
2  𝐶𝐼𝑒 ≥ 𝐶𝑠
0       𝐶𝐼𝑒 < 𝐶𝑠
 
(4-6d) 
4.2.4 Model parameters estimated by single-column experiments 
In our previous work an axial dispersion coefficient was calculated using available 
correlations for packed bed column. Also, the void volume, which was necessary for 
axial dispersion coefficient and phase ratio calculations, was measured using 
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thyroglobulin from bovine thyroid as a test probe. Furthermore, the mass transfer and 
equilibrium constants for early intermediates and native lysozyme (𝑘𝑜𝑣,𝑖 and 𝐾𝑒𝑞,𝑖) were 
found by least-squares fitting of the deviation of measured concentration during single-
column experiments vs. calculated for BSA model protein and native lysozyme 
respectively. The refolding kinetic constant (𝑘𝑎𝑝𝑝) was also obtained in the same manner 
for elution profile of refolded native lysozyme when low loading concentrations (5-20 
mg/mL) of denatured/reduced lysozyme were refolded on SEC. Low loading 
concentrations were used to prevent aggregation [17]. 
In this work, In order to introduce aggregation into the model, the aggregation kinetic 
constant (𝑘𝑎) and early intermediate solubility (𝐶𝑠), were determined by least squares 
fitting of measured refolded native protein concentration vs. calculated (equation 4-7) 
accomplished via the fminsearch function of MATLAB to find the parameters which 
indicated a global minimum. 
𝑓(𝑥) = ∑ (𝐶𝑏,𝑖
𝑒𝑥𝑝,𝑗 − 𝐶𝑏,𝑖
𝑓𝑖𝑡,𝑗(𝑥))2𝑗=𝑛𝑗=1   
(4-7) 
The above kinetic and thermodynamic parameters vary depending on local concentration 
of urea and DTT. In order to investigate the concentration profile of urea in SMB-SEC, 
mass transfer and equilibrium constants were found by measuring the concentration 
profile of pure urea injection on single column and minimization of deviation of 
experimental vs predicted results. The correlations for these constants have found to have 
wide errors as shown in the work of Park et al. [7], which motivated experimental 
determination of these values.  
4.2.4.1 Effect of Denaturant and Reducing Agents on Model Parameters 
The carry-over of both urea and DTT, present in the feed stream, to the refolding 
environment can influence the results of refolding. However, it should be noted that DTT 
exists in both oxidized and reduced forms, which each possess different effects on 
refolding and aggregation kinetics. Concentrations equal or higher than of 0.6 mM of 
reduced form of this reagent can completely stop the refolding of lysozyme, while both 
the reduced and oxidized forms might result in non-optimal redox couple concentration 
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ratio and indirect adverse effects [8]. Furthermore, the oxidized to reduced ratio of this 
reducing agent will change over time due to oxidation unless continuous feed preparation 
is implemented. The oxidized to reduced ratio is also dependent on the feed protein 
concentration as the protein concentration varies whereas the initial concentration of DTT 
in the feed is constant. For the above mentioned reasons the task of quantifying the 
different effects becomes challenging. DTT may be removed before introducing the feed 
stream to the continuous refolding system. In order to gain more information on possible 
effects of DTT removal, batch single-column experiments of DTT-free lysozyme 
refolding were executed and the results were compared to the cases with carry-over of 
DTT. 
The concentration profile of urea in SMB-SEC was predicted to find out more 
information about its local concentrations through the columns and separation from 
unfolded lysozyme.  Since the purpose was to study the urea and protein concentration-
waves separation, no reaction was considered. This investigation assisted in deciding 
whether further experimentations are required to find suitable functions to related kinetics 
of on-column refolding, aggregation and solubility to urea local concentrations. 
4.3  Materials and Methods 
4.3.1 Chemicals 
Reagent grade ʟ -arginine and urea, Ethylene Diamine Tetra Acetic acid (EDTA), 
lysozyme from chicken egg white, trizma® base (Tris-base), cysteine, cystine, 
BioUltradithiothreitol (DTT) solution, Trifluoric acetic acid (TFA) reagent plus grade 
and acetonitrile 0.1% TFA were purchased from Sigma-Aldrich, Canada. DIUR-500 urea 
assay kit and Red 660™ protein assay reagent were purchased from Bioassays, and G-
Biosciences, USA respectively. Superdex™ 75pg resin (34 µm average particle size) was 
purchased from GE healthcare, Canada. 
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4.3.2 Analytical Methods 
4.3.2.1 Native-protein Concentration 
A Vydac 214MS C4 column (5 µm, 250 x 4.6 mm) was used on an Agilent HPLC system 
to separate native protein from other conformations and determine its concentration in 
collected samples during protein refolding experiments on SEC. A linear acetonitrile-
water gradient with 0.1% (v/v) TFA starting at 25% acetonitrile increasing at 2.3%/min 
was used to elute the protein in 10 min. The total solvent flow rate, column temperature 
and injection volume were set at 1 mL/min, 20 ºC and 50 µL respectively.   
Concentration of native protein in samples collected during injection profile 
determination was calculated by comparing the UV absorbance of samples and native 
protein standards at 280 nm. Both standards and samples UV absorbance reading were 
carried in a Tecan M200 plate reader.  
4.3.2.2 Total-protein Concentration 
The total protein concentration in protein pool after DTT removal was determined with 
Red 660™ protein assay using microtiterplate reader in which 10 µl protein samples was 
transferred to each well, 150 µL of reagent was added and mixed using the plate reader 
(6.5 mm circular shaker), and absorbance of the mixture at 660 nm was measured after 5 
min. The total protein concentrations were calculated by comparing the fraction and 
standard protein sample absorbance.   
4.3.2.3 Urea Concentration 
The urea concentrations in samples were determined by urea assay kit (DIUR-500) using 
microtiterplate reader in which 5 µl of diluted samples were transferred to each well, 200 
µL of reagent was added and mixed using the plate reader (6.5 mm circular shaker), and 
absorbance of the mixture at 520 nm was measured after 20 min. The samples were 
diluted with water instead of refolding buffer to avoid the interference of ʟ -arginine with 
the assay (as recommended by the manufacturer).  
 68 
 
4.3.3 Protein Unfolding 
Unfolding buffer (0.1 M Tris-base, 1 mM EDTA, 6 M urea and 32 mM DTT, pH 8.1) 
was used to prepare various concentrations of denatured/reduced lysozyme. The sample 
was incubated for 2-4 h at 37 °C for lysozyme concentrations under 20 mg/mL [8] and 
above 30 mg/mL respectively. The loss of native structure was confirmed by RP-HPLC 
analysis afterwards. 
4.3.4 Protein Injection Profile 
The injection profile of protein was determined by replacing the column on ÄKTA 
purifier 100 by a piece of tubing with the same dimensions as column inlet tubing. The 
same injection loops were used for manual loading of native protein sample dissolved 
and eluted with refolding buffer. Fractions of 200 µl were collected and the concentration 
of native protein for each fraction was determined using UV absorbance.  
4.3.5 DTT Removal 
A 5 mL Hitrap desalting column (GE healthcare) was used to remove DTT from 
denatured/reduced lysozyme. The column was equilibrated with 2 CVs of unfolding 
buffer without DTT (0.1 M Tris-base, 1 mM EDTA, 6 M urea). 0.5 mL samples of 25 
mg/mL were injected on column and eluted with 1 mL/min flow rate of unfolding buffer. 
Fractions of 0.5 mL were collected and pooled for refolding experiments described in the 
next section. In order to investigate the refolding of higher concentration of DTT-free 
lysozyme, the pool of desalting stage was concentrated using 10K 4 mL Amicon® Ultra 
centrifugal filters. The pool total protein concentration was determined using total protein 
assay as described above. 
4.3.6 Single-column Batch Refolding    
A XK16/40 column (GE healthcare, Canada) packed with Superdex™75pg resins 
(column volume ~54 mL) was installed on ÄKTA purifier 100 controlled by UNICORN 
5.31 software and equipped with online pH probe, UV detector and conductivity cell. The 
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fractionation kit allows the collection of samples at desired volumes. Acetone pulse 
injection (2% (v/v)) was used to test the packing quality by comparing the peak 
symmetry and number of theoretical plates per length of column with manufacturer 
recommended criteria. 
The column was equilibrated with 2 CVs of the refolding buffer (0.1 M Tris, 1 mM 
EDTA, 2 M urea, 0.2M ʟ -arginine, 3 mM cysteine, 0.3 mM cysteine buffered at pH 8.1) 
prior to injection of 1 mL of denatured/reduced lysozyme with various concentrations 
(30, 40 and 50 mg/mL) . The sample was eluted using the same buffer and flow rate of 1 
mL/min. Fractions of 1 mL were collected and concentrations of native protein were 
determined using RPHPLC. The same procedure was followed for refolding of 
denatured/reduced lysozyme after DTT removal.  
4.3.7 Solubility Test 
Samples of 40 mg/mL DTT-free lysozyme in 0.1 M Tris-base, 1 mM EDTA, 6 M urea 
buffered at pH 8.1 were diluted using a 0.1 M Tris-base, 1 mM EDTA buffer pH 
8.1containing urea and ʟ-arginine without redox couple. The urea and ʟ-arginine 
concentrations were adjusted to result in a buffer identical to refolding buffer used during 
on-column refolding experiments considering the dilution factor. The absence of redox 
couple quenches the reaction at early intermediates [18]. DTT was removed for the same 
reason to avoid the formation of native protein during dilution experiments. The initial 
concentration of diluted sample was 8 mg/mL which was incubated overnight. The 
aggregates were precipitated by centrifuge and the concentration of solubilized protein in 
supernatant was measured by total protein assay.   
4.3.8 Urea Injection 
A sample of 6 M urea was prepared in a buffer similar to the refolding buffer 
composition with the exception of urea. No urea was used in this buffer to avoid high 
dilution factors during urea concentration measurements. 0.5 mL of this sample was 
injected on the SEC column and eluted with 1 mL/min flow rate of the same buffer while 
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collecting fractions of 1 mL. The experimental elution profile of urea was obtained by 
measuring urea concentration in the samples using urea assay kit.  
4.3.9 SMB-SEC Simulations 
After determining the necessary model parameters, the SMB-SEC operational parameters 
(i.e. external and internal flow rates and switching time) were selected using triangle 
theory. Based on this theory, inequalities of (4-8a)(a-c) correspond to a design space 
where complete separation can be achieved [20]. 
 𝐾𝑒𝑞,𝑢𝑟𝑒𝑎 < 𝑚1 < ∞ (4-8a) 
 𝐾𝑒𝑞,𝑁 < 𝑚2 < 𝑚3 <  𝐾𝑒𝑞,𝑢𝑟𝑒𝑎 (4-8b) 
−𝜀𝑝
(1 − 𝜀𝑝)
< 𝑚4 <  𝐾𝑒𝑞,𝑢𝑟𝑒𝑎 
(4-8c) 
where  𝑚𝑗 is called flow rate ratio and defined as ratio of net liquid flow rate to net solid 
phase flow rate in zone 𝑗 and 𝜀𝑝 is particle porosity.  Particle porosity was measured 
experimentally using acetone and thyroglobulin from bovine thyroid injections on single 
column. Acetone and thyroglobulin from bovine thyroid elution volume to total column 
volume ratio measures total porosity (𝜀) and void volume (𝜀𝑏) respectively and the 
particle porosity is calculated as: 𝜀𝑝 =  
𝜀−𝜀𝑏
1−𝜀𝑏
 . Total porosity, void volume and particle 
porosity were found to be 0.9, 0.34 and 0.8 respectively. The equilibrium constants for 
native lysozyme and urea were found by least-squares fitting of the deviation of 
measured concentration vs. calculated for native protein and urea when native lysozyme 
and pure urea were injected on the single column. The fitted parameters are 0.9 for urea 
and 0.44 for native lysozyme [17]. The liquid flow rate in each SMB-SEC zone is related 
to phase ratio by the following  
𝑄𝑗 =
𝑚𝑗𝑉𝑐(1 − 𝜀) + 𝑉𝑐𝜀
𝑡𝑠
 
(4-9) 
where 𝑡𝑠  is the switching time.  
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In addition to the above criteria the flow rates must be within lowest and the highest flow 
rate range which are considered 0.25 and 3 mL/min respectively. For the selected flow 
rate range, Young and Wilson-Geankoplis correlations [6] were used to determine the 
controlling mass transfer resistance by order of magnitude analysis which revealed the 
pore resistance as the major resistance component. Since this value is independent of the 
velocity the estimated model parameters are valid for the selected flow rate range.  The 
highest flow rate is determined based on maximum allowable pressure over the system 
compatible with packing and column material. Table 4-1 reports the operational 
parameters which were used during SMB-SEC simulations. 
Table 4-1. SMB-SEC operational parameter selected based on triangle theory 
Phase 
ratios 
𝑡𝑠 
(min) 
𝑄𝐷=𝑄1 
(mL/min) 
𝑄2 
(mL/min) 
𝑄3 
(mL/min) 
𝑄4=𝑄𝑊 
(mL/min) 
𝑄𝐸𝑥 
(mL/min) 
𝑄𝐹 
(mL/min) 
𝑄𝑅𝑎 
(mL/min) 
𝑚1=1.3 
𝑚2=0.6 
𝑚3=0.8 
𝑚4=0.3 
2.7 2.72 1.66 1.96 1.21 1.04 0.30 0.74 
3 2.39 1.47 1.74 1.08 0.92 0.26 0.66 
3.3 2.17 1.34 1.58 0.98 0.84 0.24 0.64 
The continuous and batch process performance indicators are defined as: 
𝑅𝑏,𝑒𝑥𝑝 =
𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒
𝐿𝑉𝑝𝑢𝑙𝑠𝑒
 
(4-10a) 
𝑅𝑐,𝑝𝑟𝑒𝑑 =
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝐶𝑆𝑆 𝑄𝑅𝑎
𝑄𝐹𝐶𝑓,𝑈 
 
(4-10b) 
Where 𝑅𝑏 and 𝑅𝑐,𝑝𝑟𝑒𝑑 are experimental and predicted solubilized lysozyme recovery for 
batch and continuous refolding respectively.  𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒 is sum of solubilized protein mass 
collected in fractions, 𝑉𝑝𝑢𝑙𝑠𝑒 injection volume,  𝐿 lysozyme loading concentration and 
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝐶𝑆𝑆  predicted average concentration of solubilized protein at cyclic steady state.  
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𝑃𝑟𝑏,𝑒𝑥𝑝 =
𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒
𝑉𝐶𝑡𝑒
 
(4-11a) 
𝑃𝑟𝑐,𝑝𝑟𝑒𝑑 =
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝐶𝑆𝑆 𝑄𝑅𝑎
𝑁𝑡𝑉𝐶
 
(4-11b) 
where 𝑃𝑟𝑏,𝑒𝑥𝑝, 𝑃𝑟𝑐,𝑝𝑟𝑒𝑑, 𝑡𝑒, 𝑉𝑐, and 𝑁𝑡 are experimental and predicted volumetric 
productivity for batch and continuous configurations, elution time of protein for batch 
experiments, volume of the column and total number of columns used for SMB-SEC 
respectively. 
𝑃𝑐,𝑝𝑟𝑒𝑑 =
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝐶𝑆𝑆
𝐶𝑠𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝐶𝑆𝑆 + 𝐶𝑢𝑟𝑒𝑎.𝑅𝑎
𝐶𝑆𝑆  
(4-12) 
𝑃𝑐,𝑝𝑟𝑒𝑑 is the predicted product purity. 
𝐵𝑐𝑏,𝑒𝑥𝑝 =
𝑄𝑏𝑡𝑒
𝑀𝑠𝑜𝑙𝑢𝑏𝑙𝑒
 
(4-13a) 
𝐵𝑐𝑐,𝑝𝑟𝑒𝑑 =
𝑄𝐷
𝐶𝑆𝑜𝑙𝑢𝑏𝑙𝑒.𝑅𝑎
𝐶𝑆𝑆 𝑄𝑅𝑎
 
(4-13b) 
where 𝐵𝑐𝑏,𝑒𝑥𝑝 and 𝐵𝑐𝑐,𝑝𝑟𝑒𝑑 are experimental and predicted buffer consumption and 𝑄𝑏 is 
elution flow rate used for single column batch experiments. 
4.4 Results and Discussions  
4.4.1 Single-column Batch Refolding  
When 1 mL of 30, 40 and 50 mg/mL of denatured/reduced lysozyme was refolded on 
SEC, although no protein signal was observed for aggregates, the refolding yield values 
(70, 50 and 40%) suggested formation of insoluble aggregates and in-column 
precipitation of these species. In order to decide whether aggregation is kinetically 
controlled by competition of refolding and aggregation or if a critical concentration is 
required, two models were examined to predict the results of lysozyme 
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refolding/aggregation on SEC for the concentration ranges used in this work as well as 
our previous work (described in section 4.2.3) [17] . Figure 4-3 shows that the 
assumption that thermodynamic condition for aggregation formation is always satisfied 
does not provide a satisfactory agreement between experimental and predicted results. 
 
Figure 4-3. Experimental vs predicted elution profile of native refolded lysozyme 
assuming thermodynamic condition for aggregation formation is always satisfied.  
Since the competing reaction rates are dependent on local concentration of protein the 
experimental injection profile of the protein was measured and used instead of commonly 
used simplified rectangular injection profile to provide a more accurate representation of 
the local protein concentrations. As shown in Figure 4-4 Gaussian type functions provide 
a good representation of the injection profiles of the protein in the system under study. It 
is evident from the same figure that the actual injection profile significantly deviates from 
the rectangular assumption. Using the experimental injection profile however, did not 
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change previously estimated model parameters namely mass transfer and equilibrium 
constants for kinetic species (data not shown).  
 
Figure 4-4. Experimental injection profile of lysozyme and its comparison with 
simplified rectangular injection profile. 
The experimental injection profile was then introduced to the model. Nevertheless, the 
model prediction was not satisfactory (as shown on Figure 4-3) suggesting that the model 
is not adequate and thermodynamic condition for aggregation is not satisfied for the 
whole concentration range. In other words, aggregation should be only introduced to the 
model when the local protein concentration exceeds a critical concentration (i.e. 
solubility of early intermediate species). As illustrated in Figure 4-5 the modified model 
considering a critical concentration and experimental injection profile of the protein 
provides an improved agreement between experimental and predicted results. The two 
fitted parameters namely aggregation kinetic constant (𝑘𝑎) and early intermediate 
solubility (𝐶𝑠) however were found to be correlated and multiple solutions were obtained 
for minimization problem. Consequently, the solubility parameter was measured 
experimentally as described in section 4.3.7. The experimental and fitted parameters were 
4.4±0.9 mg/mL and 0.05±2.8 x 10
-5 
mL/mg min respectively. 
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Figure 4-5. Experimental vs predicted elution profile of native refolded lysozyme using 
both simplified rectangular and experimental injection profiles. 
4.4.2 Single-column Batch Refolding of DTT-free Lysozyme  
The apparent refolding kinetic of DTT-free lysozyme found to be equal to lysozyme 
refolding with carry-over of DTT within experimental error. It can be seen in Figure 4-6 
that 𝑘𝑎𝑝𝑝=0.08 min
-1 
adequately predicts the result of DTT-free lysozyme refolding on 
SEC at loading concentrations of ~5 and 10 mg/mL and 1 mL injection volume. This is 
because the refolding kinetic constant with DTT carry-over was measured for a system 
with high dilution factor (~50 times) and the carry-over of reduced DTT was 
insignificant. 
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Figure 4-6. Experimental vs predicted elution profile of refolded native lysozyme for 
DTT- free lysozyme loading concentrations of 5 mg/mL and 10 mg/mL; DTT-free 
lysozyme obtained from desalting column was pooled, concentrated and injected on SEC.  
4.4.3 Model Parameters for Urea 
The experimental mass transfer and equilibrium constants for urea 
(𝑘𝑜𝑣,𝑢𝑟𝑒𝑎 and  𝐾𝑒𝑞,𝑢𝑟𝑒𝑎) were found to be 51.97±0.02 min
-1
 and 0.9±0.1. Figure 4-7 
illustrates the experimental versus predicted urea concentration at the column outlet using 
experimentally measured mass transfer parameters as well as parameters calculated by 
available correlations. It was observed that correlations do not provide an accurate 
prediction of urea elution profile. For this reason, the fitted values of mass transfer 
parameters were applied to predict the local concentrations of urea through the SMB-SEC 
columns and at the raffinate stream. 
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Figure 4-7. Experimental vs predicted elution profile of urea; predicted with the 
coefficients taken from correlations and coefficients taken from independent experiments. 
4.4.4 SMB-SEC Model Validation  
Park et al. [7] have studied the refolding of DTT-free lysozyme (1.78 mg/mL) in a 1-1-1-
1 four zone SMB-SEC. The model developed in the current work, was initially tested 
against their experimental results and native protein concentration and refolding yield at 
product outlet was predicted with 9.3% and 5.5% relative error respectively. Although, 
the discrepancy between model prediction and existing experimental results is not 
significant, the model must be tested under various operation conditions such as loading 
concentrations for further validation. 
It can be seen from Figure 4-8 that for the configuration used in this work, there is an 
overlap between urea and protein concentrations. The overlapping area corresponds to the 
length of two columns in SMB-SEC. This observation suggest that more experimentation 
may be required to relate the model parameters namely apparent refolding kinetic 
constant, solubility of early intermediates and aggregation constant to local concentration 
 78 
 
of urea in order to account for the effect of dynamic chemical environment on these 
parameters [21].  
 
Figure 4-8. Mid cycle concentration profiles of urea and early intermediates through 
SMB-SEC columns for the operating condition reported in Table 4-1 and 10 mg/mL 
DTT-free lysozyme loading concentration (The number of switching time was fixed at 30 
in order to assure steady state operation); (A) ts =2.7 min, (B) ts =3 min and (C) ts =3.3 
min. 
Urea has demonstrated both denaturing and protective osmolyte properties [22,23]. For 
example, no native conformation has been observed for lysozyme at urea concentrations 
above 5 M [24] whereas urea concentrations under 3 M seem to increase the stability of 
the collapsed-globular state of poly (N-isopropylacrylamide) and shift the 
unfolded/folded equilibrium towards folded conformations [22]. Under the current 
operating conditions, as can be seen in Figure 8, urea concentration varies along the 
columns between no excess urea compared to the refolding buffer (total urea 
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concentration of 2M) and about 50% of the urea present in the feed (total urea 
concentration of about 5M). Since the model parameters were measured using the 
refolding buffer during single-column experiments with much higher dilution factor, the 
developed model with constant kinetic and thermodynamic parameters may over-predict 
the native protein concentration at SMB-SEC product outlet as it disregards lower 
refolding kinetics and equilibrium in higher urea concentrations. Over-prediction of the 
native protein concentration results in under-prediction of protein aggregation. However, 
this error may be balanced by higher solubility of early intermediates and reduced 
aggregation in higher urea concentrations.  
On the other hand, simulations for the above operating conditions showed no urea in the 
raffinate stream, indicating the refolding reaction will continue off-column with the same 
kinetics as single column experiments to recover the desired product. Therefore in this 
work, process performance indicators were defined based on total solubilized protein 
rather than native protein. And accordingly, it is suggested that the model is tested against 
experiments for total solubilized protein. It should be noted that in the presence of ʟ -
arginine, aggregates precipitate and solubilized protein only include early intermediates 
and native protein conformations.  
4.4.5 SMB-SEC Performance 
Based on above discussion, the model with constant parameters was used to study the 
effect of operating parameters on process performance indicators namely solubilized 
protein recovery and productivity, product purity at the raffinate outlet and buffer 
consumption . Table 4-2 shows the results of SMB-SEC simulations at operating 
condition corresponding to switching time of 3 min in Table 4-1 for feed concentrations 
of 5-40 mg/mL. The corresponding SEC experimental results are also reported when data 
was available from experiments. 
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Table 4-2. SMB-SEC simulations feed concentrations of 5-40 mg/mL, switching time of 
3 min and available corresponding SEC experimental results. SEC results are reported for 
elution flow rate of 1 mL/min and injection volume of 0.5 mL. 
𝐶𝑓,𝑈  
(mg/mL) 
𝑅𝑐,𝑝𝑟𝑒𝑑 
(-) 
𝑃𝑟𝑐,𝑝𝑟𝑒𝑑 
(mg/mL h) 
𝐵𝑐𝑐,𝑝𝑟𝑒𝑑 
(mL/mg) 
𝑅𝑏,𝑒𝑥𝑝 
(-) 
𝑃𝑟𝑏,𝑒𝑥𝑝 
(mg/mL h) 
𝐵𝑐𝑏,𝑒𝑥𝑝 
(mL/mg) 
5 1.0 1.6 1.9 1.0 0.1 13.6 
10 1.0 3.0 1.0 1.0 0.2 6.8 
15 1.0 4.8 0.6 - - - 
20 0.8 5.4 0.5 1.0 0.3 3.4 
40 0.5 6.0 0.5 0.9 0.6 1.9 
It can be seen that, although productivity increases and buffer consumption is reduced at 
higher feed concentrations, the recovery decreases for concentrations equal and above 20 
mg/mL showing aggregation formation. As expected the productivity and buffer 
consumption in SMB-SEC were significantly improved compared to SEC. The buffer 
consumption can be further reduced by using a closed loop configuration and buffer 
recycling. For oxidative refolding however, the redox couple ratio might change over 
time resulting in non-optimal buffer composition. It was previously demonstrated that 
lysozyme refolds at higher pH values closer to its isoelectric point without the need for 
redox couple while aggregation was suppressed due to the presence of ʟ -arginine and the 
refolding yield did not show a significant change [18]. Based on the characteristics of the 
protein under study oxidative refolding without the need for a redox couple might offer 
advantages in terms of chemical cost, buffer preparation and storage but further kinetic 
studies are required to compare refolding with and without a redox couple. As mentioned 
100% purity was estimated for SMB-SEC as predictions showed no urea at the raffinate 
stream.  
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In order to explore the effect of switching time, the simulations were also carried out for 
the above feed concentration range and operating conditions corresponding to switching 
times of 2.7 and 3.3 min. As shown in Table 4-3, in the studied concentration range 
switching time of 2.7 min resulted in highest productivity compared to switching times of 
3 and 3.3 min and up to 50% improvement was observed for loading concentration of 5 
mg/mL, while recovery and buffer consumption did not vary significantly by change of 
the switching time. The same trend was observed for switching times of 2.7 and 3.3 min 
in terms of recovery drop for concentrations equal and above 20 mg/mL as switching 
time of 3 min. 
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Table 4-3. SMB-SEC productivity simulations for feed concentrations of 5-40 mg/mL 
and various operation conditions corresponding to three different switching times used in 
this work. 
𝐶𝑓,𝑈  
(mg/mL) 
𝑡𝑠 
(min) 
𝑃𝑟𝑐,𝑝𝑟𝑒𝑑 
(mg/mL h) 
5 2.7 1.8 
 
10 2.7 3.6 
15 2.7 5.4 
20 2.7 6.0 
40 2.7 7.2 
5 3 1.6 
10 3 3.0 
15 3 4.8 
20 3 5.4 
40 3 6.0 
5 3.3 1.2 
10 3.3 3.0 
15 3.3 4.2 
20 3.3 5.4 
40 3.3 6.0 
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4.5 Conclusions 
This work illustrates important considerations for utilizing single-column data towards 
design/operation of an SMB process. Our findings showed: 1) at higher local protein 
concentrations aggregation occurs when local protein concentration exceeds a critical 
concentration (i.e. solubility of early intermediates); 2) if DTT is to be removed from 
denatured/reduced lysozyme to avoid further complexity in developing a model and the 
adverse effect of this reagent on refolding kinetics, the single-column parameters 
obtained with DTT carry-over are still valid provided they were obtained for a column 
with high dilution factor; 3) a model with constant kinetic and thermodynamic parameters 
may not result in accurate prediction of native protein; however, 4) under the operation 
condition studied, the refolding reaction will continue off-column as predictions showed 
no urea in the raffinate stream ; and 5) it is suggested that the model is tested against total 
solubilized protein rather than native protein and the process performance indicators are 
defined accordingly; finally 6) the prediction of SMB-SEC performance for loading 
concentrations of 5-40 mg/mL, using the model with constant parameters, showed that 
increasing the concentration increases the productivity and decreases the buffer 
consumption however at concentrations equal to and higher than 20 mg/mL aggregates 
are formed and precipitate in the column. The operating condition corresponding to 
lowest switching time resulted in highest productivity and no significant effect on 
recovery and buffer consumption. 
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Chapter 5  
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5 Summary and Future Work Recommendations 
In spite of the advances made to date for expression of protein-therapeutics using E. coli 
host [1], the existing technologies to recover active and high-purity product still suffer 
from low refolding yields, volumetric productivities and high buffer consumption for 
commercial scale production which impose constraints in terms of time and cost [2]. This 
research work focused on various process development and optimization strategies to 
improve on above mentioned process performance indicators in size exclusion 
chromatography which has been extensively used at lab scale for protein refolding 
purpose. The outcome of this research is meant to be general, with broad application for 
cost effective high-throughput inclusion-body-based protein production. 
Chapter 2 of this thesis presents a multivariable investigation of various parameters of the 
refolding buffer namely buffer pH, sodium chloride and ʟ-arginine concentrations.  It was 
illustrated that the benefit of using ʟ-arginine is twofold as, in addition to preventing 
aggregation of lysozyme for loading concentrations of up to 40 mg/mL, it introduced the 
possibility of adjusting the buffer redox potential by controlling the pH to assist 
reformation of disulfide bridges without the need for costly redox couple chemicals. ʟ-
arginine also reduced the pore accessibility for small molecules of urea and DTT at 
higher protein concentrations indicating gradual removal of these agents which may be an 
additional mechanism by which this additive prevents aggregation in size exclusion 
chromatography. Further experimentation is however required to test these observations 
for other protein systems.  
In Chapter 3, various methods were introduced for high-throughput measurements of 
mass transfer parameters and distribution coefficients of refolding kinetic species by 
single-column experiments in order to establish an experimentally-verified mathematical 
model. These methods included non-reactive native protein, model protein compounds 
and equilibrium experiments to extract characteristic information for native protein, early 
collapsed intermediates and native-like intermediates respectively. Although this was 
only demonstrated for the model protein (lysozyme), the same methods can be used for 
other oxidative and non-oxidative refolding cases. It was also demonstrated that the 
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above mentioned parameters from size exclusion chromatography may be improperly 
estimated due to non-specific interaction of species with the chromatography gel even 
when ʟ-arginine was used; which is commonly suggested for reduced protein interaction 
with surfaces and increased recovery in various chromatography methods [3–5]. In 
addition, the importance of kinetic studies in deciding on an appropriate refolding 
additive was discussed. In this work, ʟ-arginine additive was found to prevent 
aggregation without compromising the speed of lysozyme refolding.  
Finally, investigations on the suitability of utilizing single-column data towards 
prediction of the behavior of the protein in multi-column continuous simulated moving 
bed size exclusion chromatography (SMB-SEC) and design/operation of a continuous 
process were carried out; presented in Chapter 4 of this thesis. The SMB-SEC technology 
offers many advantages compared to single-column processing, including increased 
productivity per unit mass of solid phase, lower solvent consumption, and less diluted 
products all of which makes it an attractive technology for future industrial applications. 
Since operation of a SMB-SEC unit includes more degrees of freedom compared to 
single-column operation, a systematic optimization is essential to obtain the operating 
parameter setting (s) that result in optimum process performance indicators. Accordingly, 
a robust mathematical model is a necessary tool for successful operation of a SMB-SEC. 
Therefore, the model that was developed in Chapter 3 was modified to extend its 
applicability for SMB-SEC. The prediction of unfolded protein and urea concentrations 
through a SMB-SEC showed lower dilution factors compared to single-column operation 
in this work. As a lower dilution factor results in higher local protein concentrations, 
protein aggregation was introduced into the model by introduction of a critical 
concentration (i.e. solubility of early intermediates) above which aggregates are formed 
with second-order rate kinetics of aggregation.  Lower dilution factor also translates to a 
higher denaturant local concentration, influencing measured kinetic and thermodynamic 
parameters by single-column experiments.  
Therefore, a model with constant kinetic and thermodynamic parameters may not result 
in accurate prediction of native to early intermediate protein ratio and an under-prediction 
of total solubilized protein concentration at the product line. However, if under various 
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operation settings no or very low concentration of denaturant exist in the product line, as 
it was the case in this work based on simulations, the refolding reaction will continue off-
column to recover protein as functional native protein. Consequently, the process 
performance indicators were defined based on total solubilized protein at the product 
outlet (early intermediates and native protein). As a result the model with constant kinetic 
and thermodynamic parameters can be used to predict the solubilized protein recovery 
and find the operational space that meets an appropriate criterion for recovery where in-
column aggregation and precipitation is mainly prevented and productivity and buffer 
consumption criteria are optimized. Experimentation on SMB-SEC systems is still 
required in order to evaluate the validity of this approach under various operating 
conditions.  
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Appendices 
Appendix A: MATLAB Codes 
A.1 Parameter fitting for model without aggregation 
clear all 
clc 
format short e 
  
x0=0.1 ;    % initial guess-refolding reaction rate constant (min-1) 
lb=0;  % lower bound  
ub=1;  % upper bound    
                                                           
options = optimset('Display','iter'); 
 
[x,fval] = fmincon(@functioncal,x0,[],[],[],[],lb,ub,[],options);         
% Returns the value of the objective function functioncal at the 
solution x 
 
function f=functioncal(x)      
  
global NPLATE 
global N 
global CfI 
global tpulse 
  
%----------------------------------------------------------------------                                                                               
NPLATE = 100; % Number of plates                                                              
N  = 4 * NPLATE; % Number of unknowns                                                           
  
%---------------------------------------------------------------------- 
% transferring experimental data 
 
CexpN=[0.00 0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
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0.01    0.00    0.00    0.01 
0.03    0.02    0.00    0.02 
0.06    0.07    0.05    0.02 
0.09    0.12    0.09    0.00 
0.08    0.17    0.08    0.00 
0.10    0.22    0.13    0.06 
0.13    0.27    0.17    0.19 
0.19    0.33    0.20    0.23 
0.20    0.45    0.26    0.35 
0.25    0.51    0.35    0.44 
0.27    0.65    0.37    0.53 
0.31    0.66    0.41    0.62 
0.35    0.73    0.43    0.68 
0.41    0.82    0.47    0.74 
0.42    0.88    0.49    0.76 
0.45    0.90    0.51    0.78 
0.34    0.77    0.48    0.70 
0.19    0.49    0.37    0.57 
0.15    0.36    0.23    0.44 
0.08    0.26    0.15    0.33 
0.08    0.22    0.12    0.23 
0.08    0.17    0.09    0.24 
0.06    0.19    0.09    0.22 
0.07    0.15    0.07    0.17 
0.05    0.14    0.06    0.14 
0.06    0.12    0.03    0.15 
0.07    0.10    0.02    0.14 
0.05    0.09    0.02    0.10 
0.03    0.08    0.01    0.10 
0.05    0.07    0.00    0.09 
0.05    0.05    0.00    0.08 
0.03    0.02    0.00    0.00 
0.01    0.00    0.00    0.00 
0.02    0.00    0.00    0.00 
0.02    0.00    0.00    0.00 
0.01    0.00    0.00    0.00 
0.01    0.00    0.00    0.00 
0.01    0.00    0.00    0.00 
0.01    0.00    0.00    0.00 
0.01    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00 
]; 
   
%---------------------------------------------------------------------- 
%ODE integration 
  
t0 = 0; 
tf= 60; 
y0 = zeros(N,1); 
  
tspan= linspace (t0,tf,61); 
f = 0;  
  
%------------------------------- 
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CfIm = [5 10 10 20]; % loading concentration (mg cm-3)                                                   
tpulsem = [1 1 0.5 0.5]; % Injection time (min)                                                
  
for j=1:4 
     
    CfI = CfIm (j); 
    tpulse = tpulsem (j); 
      
    [T, Y]=ode15s(@(t,y)elution_profile(t,y,x),tspan,y0);  
  
%---------------------------------------------------------------------- 
% calculating objective function 
  
Cexp= CexpN (:,j); 
  
for i=1:length(T)  
     
    f=f+(Y(i,3*N/4)-Cexp(i))^2 ; 
    
end  
  
end  
 
 
function dydt = elution_profile(t, y, x) 
  
global NPLATE 
global N 
global CfI 
global tpulse 
  
%   --------------- pre-allocating the variables 
 
L = 27; % Column length (cm) 
                                                              
h = L / (NPLATE - 1); % Computing the step size                                                     
  
AREA = 2; % Column cross-section (cm2)                                                      
  
E = 0.34; % Bed void volume fraction (-) 
                                                                
Q = 1; % Flow rate (mL/min)                                                                  
  
U = Q / (E * AREA); % Velocity (cm min-1)                                                        
  
P = (1 - E) / E; % Phase ratio 
                                                         
DL = 10 * U * 17e-4 * E; % Dispersion coefficient (cm2 min-1) 
                                                   
KsecN = 0.44; % Native protein distribution coefficient (-) 
                                                             
KsecI = 0.08; % Early intermediate protein distribution coefficient (-)                                                             
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KovI = 2.69; % Early intermediate overal mass transfer coefficient 
(min-1) 
                                                                
KovN = 17.29; % Native protein overal mass transfer coefficient (min-1) 
                                                               
Krxn = x(1,1); % Refolding reaction rate constant (min-1) 
                                                               
%---------------------------------------------------------------------- 
%Constants used in function 
  
B1 = U / (2* h); 
C1 = DL / (h ^2); 
B2= U/ (12 * h);  
C2=DL / (12 * (h ^2));  
  
dydt = zeros(N,1); 
KZF = lt(t, tpulse); 
CfN = 0;  
%----------------------------------------------------------------------
---- 
%                       Defining the ODEs 
  
  
dydt(1) =  C1 * ( KZF * CfI - 2 * y(1) +  y(2)) - B1 * (-KZF * CfI + 
y(2)) - P * KovI * (KsecI * y(1) - y(N/4+1)) -Krxn* y(1); 
  
  
dydt(N/4+1) = KovI * ( KsecI * y(1) - y(N/4+1)) - Krxn * y(N/4+1);  
  
  
dydt(N/2+1) = C1 * (KZF * CfN - 2 * y(N/2+1) +  y(N/2+2)) - B1 * (- KZF 
* CfN + y(N/2+2))- P * KovN * (KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn * 
y(1); 
     
  
dydt(3*N/4+1) = KovN *( KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn * 
y(N/4+1); 
          
  
dydt(2) = C2 * ( - KZF * CfI + 16 * y(1) - 30 * y(2) + 16 * y(3) - 
y(4)) - B2 * (KZF * CfI - 8 * y(1) + 8 * y(3) - y(4)) - P * KovI * 
(KsecI * y(2) - y(N/4+2)) - Krxn * y(2);  
  
  
dydt(N/4+2) = KovI * ( KsecI * y(2) - y(N/4+2)) - Krxn * y(N/4+2);  
  
  
dydt(N/2+2) = C2 * (-KZF * CfN + 16 * y(N/2+1) - 30 * y(N/2+2) + 16 * 
y(N/2+3) - y(N/2+4)) - B2 * (KZF * CfN - 8 * y(N/2+1) + 8 * y(N/2+3) - 
y(N/2+4))- P * KovN * (KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * y(2);  
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dydt(3*N/4+2) = KovN *( KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * 
y(N/4+2);  
             
        
for I=3:N/4-2 
        
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) - 
y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI 
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I);  
  
  
dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I);  
  
  
dydt(N/2+I) = C2 * (- y (N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 
16 * y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 
* y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) 
+ Krxn * y(I); 
        
  
dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) -y(3*N/4+I)) + Krxn * 
y(N/4+I); 
                      
end 
  
  
        
dydt(N/4-1) = C2 * (- y (N/4-3) + 16 * y(N/4-2) - 30 * y(N/4-1) + 16 * 
y(N/4) - y(N/4)) - B2 * (y(N/4-3) - 8 * y(N/4-2) + 8 * y(N/4) - y(N/4)) 
- P * KovI * (KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/4-1);  
  
  
dydt(N/2-1) = KovI *( KsecI * y(N/4-1)-y(N/2-1)) - Krxn * y(N/2-1);  
  
  
dydt(3*N/4-1) = C2 * (- y (3*N/4-3) + 16 * y(3*N/4-2) - 30 * y(3*N/4-1) 
+ 16 * y(3*N/4) - y(3*N/4)) - B2 * (y(3*N/4-3) - 8 * y(3*N/4-2) + 8 * 
y(3*N/4) - y(3*N/4)) - P * KovN * (KsecN * y(3*N/4-1) - y(N-1)) + Krxn 
* y(N/4-1); 
  
  
dydt(N-1) = KovN *( KsecN * y(3*N/4-1) -y(N-1)) + Krxn * y(N/2-1);  
  
  
dydt(N/4) = C1 * (y(N/4-1) -2 * y(N/4) +  y(N/4)) - B1 * (- y(N/4-1) + 
y(N/4)) - P * KovI * (KsecI * y(N/4) - y(N/2)) - Krxn * y(N/4);   
  
  
dydt(N/2) = KovI *( KsecI * y(N/4)-y(N/2))- Krxn * y(N/2);   
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dydt(3*N/4) = C1 * (y(3*N/4-1) - 2 * y(3*N/4) + y(3*N/4)) - B1 * (-
y(3*N/4-1) + y(3*N/4)) - P * KovN *(KsecN * y(3*N/4) - y(N)) + Krxn * 
y(N/4); 
  
dydt(N) = KovN *( KsecN * y(3*N/4) -y(N)) + Krxn * y(N/2); 
 
A. 2 Parameter fitting for model with aggregation and Gaussian injection 
profile 
clear all 
clc 
format short e 
  
x0=0.1 ;  % initial guess-aggregation reaction rate constant (min-1) 
 
options = optimset('Display','iter'); 
 
[x,fval] = fminsearch(@functioncal,x0,options); 
  
function f=functioncal(x)      
  
global NPLATE 
global N 
global a 
%----------------------------------------------------------------------
----------------------------------- 
                                                                               
NPLATE = 100;     % Number of plates                                                           
N  = 4 * NPLATE;  % Number of unknowns                                                                                                                   
  
 %--------------------------------------------------------------------- 
% transferring experimental data 
 
CexpN=[0.00 0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.01    0.00    0.00    0.01    0.02 
0.01    0.00    0.03    0.02    0.00    0.02    0.04 
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0.01    0.01    0.06    0.07    0.05    0.02    0.04 
0.07    0.04    0.09    0.12    0.09    0.00    0.09 
0.09    0.07    0.08    0.17    0.08    0.00    0.09 
0.10    0.11    0.10    0.22    0.13    0.06    0.13 
0.19    0.18    0.13    0.27    0.17    0.19    0.20 
0.26    0.26    0.19    0.33    0.20    0.23    0.22 
0.36    0.37    0.20    0.45    0.26    0.35    0.41 
0.40    0.47    0.25    0.51    0.35    0.44    0.41 
0.57    0.58    0.27    0.65    0.37    0.53    0.54 
0.68    0.64    0.31    0.66    0.41    0.62    0.67 
0.80    0.78    0.35    0.73    0.43    0.68    0.89 
0.92    0.86    0.41    0.82    0.47    0.74    0.95 
1.11    0.95    0.42    0.88    0.49    0.76    0.99 
1.33    0.99    0.45    0.90    0.51    0.78    1.22 
1.29    0.80    0.34    0.77    0.48    0.70    1.25 
1.06    0.59    0.19    0.49    0.37    0.57    1.22 
0.77    0.40    0.15    0.36    0.23    0.44    1.03 
0.73    0.28    0.08    0.26    0.15    0.33    0.86 
0.62    0.18    0.08    0.22    0.12    0.23    0.70 
0.53    0.17    0.08    0.17    0.09    0.24    0.59 
0.42    0.13    0.06    0.19    0.09    0.22    0.48 
0.46    0.11    0.07    0.15    0.07    0.17    0.46 
0.42    0.10    0.05    0.14    0.06    0.14    0.39 
0.33    0.07    0.06    0.12    0.03    0.15    0.35 
0.36    0.05    0.07    0.10    0.02    0.14    0.33 
0.20    0.05    0.05    0.09    0.02    0.10    0.28 
0.17    0.04    0.03    0.08    0.01    0.10    0.26 
0.10    0.03    0.05    0.07    0.00    0.09    0.26 
0.05    0.00    0.05    0.05    0.00    0.08    0.22 
0.02    0.00    0.03    0.02    0.00    0.00    0.20 
0.00    0.00    0.01    0.00    0.00    0.00    0.15 
0.00    0.00    0.02    0.00    0.00    0.00    0.13 
0.00    0.00    0.02    0.00    0.00    0.00    0.11 
0.00    0.00    0.01    0.00    0.00    0.00    0.07 
0.00    0.00    0.01    0.00    0.00    0.00    0.15 
0.00    0.00    0.01    0.00    0.00    0.00    0.13 
0.00    0.00    0.01    0.00    0.00    0.00    0.11 
0.00    0.00    0.01    0.00    0.00    0.00    0.07 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
0.00    0.00    0.00    0.00    0.00    0.00    0.00 
]; 
  
 %--------------------------------------------------------------------- 
%ODE integration 
  
t0 = 0; 
tf= 60; 
y0 = zeros(N,1); 
  
tspan= linspace (t0,tf,61); 
f = 0;  
  
%------------------------------- 
am = [26.56 13.28 3.36 6.59 3.36 6.59 16.6]; 
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for j=1:7 
     
    a = am (j); 
      
    [T, Y]=ode15s(@(t,y)elution_profile(t,y,x),tspan,y0);  
  
%---------------------------------------------------------------------- 
% calculating objective function 
  
Cexp= CexpN (:,j); 
  
for i=1:length(T)  
     
    f=f+(Y(i,3*N/4)-Cexp(i))^2 ; 
    
end  
  
end  
function dydt = elution_profile(t, y, x) 
  
global NPLATE 
global N 
global a 
  
  
%   --------------- pre-allocating the variables 
 
L = 27; % Column length (cm) 
                                                              
h = L / (NPLATE - 1); % Computing the step size                                                     
  
AREA = 2; % Column cross-section (cm2)                                                      
  
E = 0.34; % Bed void volume fraction (-) 
                                                                
Q = 1; % Flow rate (mL/min)                                                                  
  
U = Q / (E * AREA); % Velocity (cm min-1)                                                        
  
P = (1 - E) / E; % Phase ratio 
                                                         
DL = 10 * U * 17e-4 * E; % Dispersion coefficient (cm2 min-1) 
                                                   
KsecN = 0.44; % Native protein distribution coefficient (-) 
                                                             
KsecI = 0.08; % Early intermediate protein distribution coefficient (-)                                                             
  
KovI = 2.69; % Early intermediate overal mass transfer coefficient 
(min-1) 
                                                                
KovN = 17.29; % Native protein overal mass transfer coefficient (min-1) 
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Krxn = 0.08; % Refolding reaction rate constant (min-1) 
                                                               
kag = x(1,1); % Aggregation reaction rate constant (mLmin-1mg-1) 
                                                              
ys = 4.4; % Early intermediate solubility (mgmL-1)                                                                  
%---------------------------------------------------------------------- 
% Constants used in function 
  
B1 = U / (2* h); 
C1 = DL / (h ^2); 
B2= U/ (12 * h);  
C2=DL / (12 * (h ^2));  
  
dydt = zeros(N,1); 
CfN = 0;  
% Gaussian function and smooth step function 
 
b = 1.5; 
c = 0.58; 
k = 100; 
KZF = a * exp(-0.5*((t-b)/c)^2); 
%---------------------------------------------------------------------- 
%                       Defining the ODEs 
  
  
dydt(1) =  C1 * ( KZF - 2 * y(1) +  y(2)) - B1 * (-KZF + y(2)) - P * 
KovI * (KsecI * y(1) - y(N/4+1)) -Krxn* y(1)- 2*  kag * (1/(1+exp(-
2*k*(y(1)-ys))))*y(1)*y(1); 
  
  
dydt(N/4+1) = KovI * ( KsecI * y(1) - y(N/4+1)) - Krxn * y(N/4+1)-2 * 
(1/(1+exp(-2*k*(y(N/4+1)-ys))))* kag *(y(N/4+1))*(y(N/4+1));  
  
  
dydt(N/2+1) = C1 * (KZF * CfN - 2 * y(N/2+1) +  y(N/2+2)) - B1 * (- KZF 
* CfN + y(N/2+2))- P * KovN * (KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn * 
y(1); 
     
  
dydt(3*N/4+1) = KovN *( KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn * 
y(N/4+1); 
          
  
dydt(2) = C2 * ( - KZF + 16 * y(1) - 30 * y(2) + 16 * y(3) - y(4)) - B2 
* (KZF - 8 * y(1) + 8 * y(3) - y(4)) - P * KovI * (KsecI * y(2) - 
y(N/4+2)) - Krxn * y(2)-2* kag * (1/(1+exp(-2*k*(y(2)-
ys))))*(y(2))*(y(2));  
  
  
dydt(N/4+2) = KovI * ( KsecI * y(2) - y(N/4+2)) - Krxn * y(N/4+2)-2 * 
(1/(1+exp(-2*k*(y(N/4+2)-ys))))* kag *(y(N/4+2))*(y(N/4+2));  
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dydt(N/2+2) = C2 * (-KZF * CfN + 16 * y(N/2+1) - 30 * y(N/2+2) + 16 * 
y(N/2+3) - y(N/2+4)) - B2 * (KZF * CfN - 8 * y(N/2+1) + 8 * y(N/2+3) - 
y(N/2+4))- P * KovN * (KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * y(2);  
  
  
dydt(3*N/4+2) = KovN *( KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * 
y(N/4+2);  
             
         
for I=3:N/4-2 
        
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) - 
y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI 
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)-
ys))))* kag *(y(I))*(y(I));  
  
  
dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 * 
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* kag *(y(N/4+I))*(y(N/4+I));  
  
  
dydt(N/2+I) = C2 * (- y (N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 
16 * y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 
* y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) 
+ Krxn * y(I); 
        
  
dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) -y(3*N/4+I)) + Krxn * 
y(N/4+I); 
                      
end 
  
  
        
dydt(N/4-1) = C2 * (- y (N/4-3) + 16 * y(N/4-2) - 30 * y(N/4-1) + 16 * 
y(N/4) - y(N/4)) - B2 * (y(N/4-3) - 8 * y(N/4-2) + 8 * y(N/4) - y(N/4)) 
- P * KovI * (KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/4-1)-2* 
(1/(1+exp(-2*k*(y(N/4-1)-ys))))* kag *(y(N/4-1))*(y(N/4-1));  
  
  
dydt(N/2-1) = KovI *( KsecI * y(N/4-1)-y(N/2-1)) - Krxn * y(N/2-1)-2 * 
(1/(1+exp(-2*k*(y(N/2-1)-ys))))* kag *(y(N/2-1))*(y(N/2-1));  
  
  
dydt(3*N/4-1) = C2 * (- y (3*N/4-3) + 16 * y(3*N/4-2) - 30 * y(3*N/4-1) 
+ 16 * y(3*N/4) - y(3*N/4)) - B2 * (y(3*N/4-3) - 8 * y(3*N/4-2) + 8 * 
y(3*N/4) - y(3*N/4)) - P * KovN * (KsecN * y(3*N/4-1) - y(N-1)) + Krxn 
* y(N/4-1); 
  
  
dydt(N-1) = KovN *( KsecN * y(3*N/4-1) -y(N-1)) + Krxn * y(N/2-1);  
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dydt(N/4) = C1 * (y(N/4-1) -2 * y(N/4) +  y(N/4)) - B1 * (- y(N/4-1) + 
y(N/4)) - P * KovI * (KsecI * y(N/4) - y(N/2)) - Krxn * y(N/4)- 2 * 
(1/(1+exp(-2*k*(y(N/4)-ys))))* kag *(y(N/4))*(y(N/4));   
  
  
dydt(N/2) = KovI *( KsecI * y(N/4)-y(N/2))- Krxn * y(N/2)-2 * 
(1/(1+exp(-2*k*(y(N/2)-ys))))* kag *(y(N/2))*(y(N/2));   
  
  
dydt(3*N/4) = C1 * (y(3*N/4-1) - 2 * y(3*N/4) + y(3*N/4)) - B1 * (-
y(3*N/4-1) + y(3*N/4)) - P * KovN *(KsecN * y(3*N/4) - y(N)) + Krxn * 
y(N/4); 
  
dydt(N) = KovN *( KsecN * y(3*N/4) -y(N)) + Krxn * y(N/2); 
A.3 SMB-SEC  
clear all 
clc 
format long 
  
global NP 
  
global n1 
global n2 
global n3 
  
global N 
  
global QF 
  
global QD 
global Q2 
global Q3 
global Q4 
  
global CfI 
global CfN 
                                        
NP = 50; % Number of plates for each column 
  
n1 = 2; %Number of columns in section 1 
n2 = 2; %Number of columns in section 2 
n3 = 2; %Number of columns in section 3  
n4 = 2; %Number of columns in section 4 
  
Nt = n1+n2+n3+n4; %Total number of columns 
  
Vc = 6; % Volume of each column (mL) 
  
N = 4 * NP * Nt; % Number of unknowns 
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QD = 2.4; % Eluent flow rate (mL min-1) 
QF = 0.26; % Feed flow rate (mL min-1) 
QRa = 0.66; % Raffinate flow rate (mL min-1) 
Q4 = 1.1; % Internal flow rate zone 4 and waste  
Q3 = Q4 + QRa; % Internal flow rate zone 3  
Q2 = Q4+QRa-QF; %Internal flow rate zone 2 
   
CfI = 30; % Feed concentration mg mL-1 
CfN = 0; 
  
Nswitch = 30; % Number of switch times 
  
%---------------------------------------------------------------------- 
% ODE integration 
  
y0 = zeros(N,1); 
y1 = zeros(1,NP); 
y2 = zeros(1,NP); 
y3 = zeros(1,NP); 
y4 = zeros(1,NP); 
RaI =zeros (Nswitch,1); 
RaN = zeros (Nswitch,1); 
ExI = zeros (Nswitch,1); 
ExN = zeros (Nswitch,1); 
RecI = zeros (Nswitch,1); 
RecN = zeros (Nswitch,1); 
PrN = zeros (Nswitch,1); 
BcN = zeros (Nswitch,1); 
 
fid1 = fopen('profileI.txt','w');  
fprintf(fid1,'%6s %6s %12s 
%12s\r\n','k','j','Location','Intermediate'); 
fid2 = fopen('profileN.txt','w'); 
fprintf(fid2,'%6s %6s %12s %12s\r\n','k','j','Location','Native'); 
  
for k=1:Nswitch 
                                                  
t0 = 0; 
ts= 3; % Switch time 
tint = 101; 
  
tspan= linspace(t0,ts,tint); 
  
[T, Y] = ode15s(@SMB_Simulation, tspan, y0); 
  
  
Yout = zeros (length(T),Nswitch*N); 
  
Yout(:,(k-1)*N+1:k*N)= Y(:,1:N); 
  
  
if (mod(k,8)== 0) 
  
for j=1:10:tint %beginning, mid and end of each cycle 
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 for I=NP/10:NP/10:N/4; %every 5plate 
   
     
fprintf(fid1,'%12d %12d %12d %4.2f\r\n',k,j,I,Yout(j, (k-1)*N +I)); % I 
concentration profile along the SMB columns 
fprintf(fid2,'%12d %12d %12d %4.2f\r\n',k,j,I,Yout(j, (k-1)*N +N/2+I)); 
% N concentration profile along the SMB columns 
     
 end 
 end  
  
end  
  
  
RaI(k,1) = (trapz(T,Yout(:,(k-1)* N + (n1+n2+n3)* NP)))/ ts; % Cyclic 
steady state concentration of I in Raffinate stream 
RaN(k,1) = (trapz(T,Yout(:,(k-1)* N + N/2+(n1+n2+n3)* NP)))/ ts;% 
Cyclic steady state concentration of N in Raffinate stream 
ExI(k,1) = (trapz(T,Yout(:,(k-1)* N+ n1* NP)))/ ts ;% Cyclic steady 
state concentration of I in Extract stream 
ExN(k,1) = (trapz(T,Yout(:,(k-1)* N+ N/2+n1* NP)))/ ts;% Cyclic steady 
state concentration of N in Extract stream 
WI(k,1) = (trapz(T,Yout(:,(k-1)* N + (n1+n2+n3+n4)* NP)))/ ts;% Cyclic 
steady state concentration of I in Waste stream 
WN(k,1) = (trapz(T,Yout(:,(k-1)* N + N/2+(n1+n2+n3+n4)* NP)))/ ts;% 
Cyclic steady state concentration of N in Waste stream 
  
  
  
RecN(k,1)=RaN(k,1)*(Q3-Q4)/(QF*CfI) ; %Recovery N 
RecI(k,1)=RaI(k,1)*(Q3-Q4)/(QF*CfI);%Recovery I 
PrN(k,1)= (RaN(k,1)+RaI(k,1))*(Q3-Q4)/(Nt*Vc);% Volumetric productivity 
in terms of solubilized protein (mg mL-1 min-1) 
BcN(k,1)= QD/ ((RaN(k,1)+RaI(k,1))*(Q3-Q4));% Buffer consumption (mL 
mg-1) 
  
  
for I=1:NP % store column 1 information @ tint 
     
y1(1,I) = Y(tint,I); 
y2(1,I) = Y(tint,N/4+I); 
y3(1,I) = Y(tint,N/2+I); 
y4(1,I) = Y(tint,3*N/4+I); 
  
end  
  
for J=0:Nt-2 % switching column in direction of solid movement  
 
for I=1:NP 
        Y(tint,I+J*NP) = Y(tint,I+(J+1)*NP); 
        Y(tint,N/4+I+J*NP)= Y(tint,N/4+I+(J+1)*NP); 
        Y(tint,N/2+I+J*NP)= Y(tint, N/2+I+(J+1)*NP); 
        Y(tint,3*N/4+I+J*NP)= Y(tint,3*N/4+I+(J+1)*NP); 
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end 
end  
  
for I=1:NP  
        Y(tint,N/4-NP+I)= y1(1,I);  
        Y(tint,N/2-NP+I)= y2(1,I); 
        Y(tint,3*N/4-NP+I)= y3(1,I); 
        Y(tint,N-NP+I)= y4(1,I);  
end  
  
y0 = Y(tint,:).'; % Initial condition for new cycle  
  
   
end 
  
fclose(fid1); 
fclose(fid2); 
 
function dydt = SMB_Simulation(t,y) 
  
global NP 
  
global n1 
global n2 
global n3 
  
global N 
  
global QF 
  
global QD 
global Q2 
global Q3 
global Q4 
  
global CfI 
global CfN 
  
  
%   --------------- pre-allocating the variables 
AREA = 0.78; % Column cross section (cm2) 
E = 0.34; % Bed void volume fraction (-)                                                                   
L = 8; % Column length (cm)                                                                    
KsecI = 0.08; % Equilibrium constant for Intermediate protein (-) 
KsecN = 0.44; % Equilibrium constant for Native protein (-) 
KovI = 2.69; % Mass transfer coefficient for Intermediate protein (min-
1)  
KovN = 17.29; % Mass transfer coefficient for Native protein (min-1)  
Krxn = 0.08; % Refolding reaction rate constant (min-1) 
Kag = 0.08; % Aggregation reaction rate constant (min-1) 
 
ys = 4.4; % Early intermediate solubility (mg mL-1) 
k = 1000;  
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h =L /(NP - 1); % Axial step size 
P = (1 - E) / E; % Phase ratio 
  
%---------------------------------------------------------------------- 
PP = n1 * NP; 
PQ = PP + n2 * NP; 
PQR =PQ + n3 * NP; 
%---------------------------------------------------------------------- 
dydt = zeros(N,1); 
%----------------------------------------------------------------------     
  
% Stage 1 &2 -------------Eluent point 
  
U = QD/(AREA * E); 
B1 = U/(2 * h); 
Dl = 10 * U * 17e-4 * E; 
C1 = Dl/(h ^ 2); 
B2=U/(12 * h); 
C2=Dl/(12 *h ^2); 
  
  
% Central second order 
  
dydt(1) = C1 * (0 - 2 * y(1) +  y(2)) - B1 * (-0 + y(2)) - P * KovI * 
(KsecI * y(1) - y(N/4+1)) - Krxn * y(1)- 2*  Kag * (1/(1+exp(-
2*k*(y(1)-ys))))*y(1)*y(1);    % I liquid   
       
  
dydt(N/4+1) = KovI * ( KsecI * y(1) - y(N/4+1)) - Krxn * y(N/4+1)-2 * 
(1/(1+exp(-2*k*(y(N/4+1)-ys))))* Kag *(y(N/4+1))*(y(N/4+1));   % I 
solid 
  
  
dydt(N/2+1) = C1 * (0 - 2 * y(N/2+1) +  y(N/2+2)) - B1 * (- 0 + 
y(N/2+2)) - P * KovN * (KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn * y(1);    
       
         
dydt(3*N/4+1) = KovN *( KsecN * y(N/2+1) - y(3*N/4+1)) + Krxn * 
y(N/4+1);                                  
  
% Central fourth order 
  
dydt(2) = C2 * ( - 0 + 16 * y(1) - 30 * y(2) + 16 * y(3) - y(4)) - B2 * 
(0 - 8 * y(1) + 8 * y(3) - y(4)) - P * KovI * (KsecI * y(2) - y(N/4+2)) 
- Krxn * y(2)-2* Kag * (1/(1+exp(-2*k*(y(2)-ys))))*(y(2))*(y(2)); 
      
  
  
dydt(N/4+2) = KovI * ( KsecI * y(2) - y(N/4+2)) - Krxn * y(N/4+2)-2 * 
(1/(1+exp(-2*k*(y(N/4+2)-ys))))* Kag *(y(N/4+2))*(y(N/4+2)); 
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dydt(N/2+2) = C2 * (-0 + 16 * y(N/2+1) - 30 * y(N/2+2) + 16 * y(N/2+3) 
- y(N/2+4)) - B2 * (0- 8 * y(N/2+1) + 8 * y(N/2+3) - y(N/2+4)) - P * 
KovN * (KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * y(2); 
     
  
  
dydt(3*N/4+2) = KovN *( KsecN * y(N/2+2) - y(3*N/4+2)) + Krxn * 
y(N/4+2); 
         
       
% Stage 3-PP --------Section 1  
         
for I=3:PP 
  
dydt(I) = C2 * (- y(I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) - 
y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI 
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)-
ys))))* Kag *(y(I))*(y(I)); 
     
  
dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 * 
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I)); 
  
  
dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16 
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 * 
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) + 
Krxn * y(I); 
     
        
dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn * 
y(N/4+I); 
  
 end 
  
% Stage (PP+1)-(PP+2) ---------Section2 
  
U = Q2 / (AREA * E); 
B1 = U / (2 * h); 
Dl = 10 * U * 17e-4 * E; 
C1 = Dl / (h ^ 2); 
B2= U / (12 * h); 
C2=Dl / (12 * h ^2); 
  
         
% Stage (PP+1)-(PQ-2) ---------Section2 
  
       
 for I=PP+1:PQ-2 
  
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) - 
y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI 
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* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)-
ys))))* Kag *(y(I))*(y(I)); 
     
  
dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 * 
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I)); 
  
  
dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16 
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 * 
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) + 
Krxn * y(I); 
     
        
dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn * 
y(N/4+I); 
      
 end  
  
% Stage (PQ-1)-(PQ) ---------Section2 
  
dydt(PQ-1) = C2 * (- y(PQ-3) + 16 * y(PQ-2) - 30 * y(PQ-1) + 16 * y(PQ) 
- y(PQ)) - B2 * (y(PQ-3) - 8 * y(PQ-2) +  8 * y(PQ) - y(PQ)) - P * KovI 
* (KsecI * y(PQ-1) - y(N/4 +PQ-1)) - Krxn * y(PQ-1)-2 * (1/(1+exp(-
2*k*(y(PQ-1)-ys))))* Kag *(y(PQ-1))*(y(PQ-1)); 
     
  
dydt(N/4+PQ-1) = KovI *( KsecI * y(PQ-1)-y(N/4+PQ-1)) - Krxn * 
y(N/4+PQ-1)-2 * (1/(1+exp(-2*k*(y(N/4+PQ-1)-ys))))* Kag *(y(N/4+PQ-
1))*(y(N/4+PQ-1)); 
  
  
dydt(N/2+PQ-1) = C2 * (- y(N/2+PQ-3) + 16 * y(N/2+PQ-2) - 30 * 
y(N/2+PQ-1) + 16 * y(N/2+PQ) - y(N/2+PQ)) - B2 * (y(N/2+PQ-3) - 8 * 
y(N/2+PQ-2) + 8 * y(N/2+PQ) - y(N/2+PQ)) - P * KovN * (KsecN * 
y(N/2+PQ-1) - y(3*N/4+PQ-1)) + Krxn * y(PQ-1); 
    
  
dydt(3*N/4+PQ-1) = KovN *( KsecN * y(N/2+PQ-1) -y(3*N/4+PQ-1)) + Krxn * 
y(N/4+PQ-1); 
  
  
dydt(PQ) = C1 * (y(PQ-1) -2 * y(PQ) +  y(PQ)) - B1 * (- y(PQ-1) + 
y(PQ)) - P * KovI * (KsecI * y(PQ) - y(N/4+PQ)) - Krxn * y(PQ)-2 * 
(1/(1+exp(-2*k*(y(PQ)-ys))))* Kag *(y(PQ))*(y(PQ)); 
    
  
dydt(N/4+PQ) = KovI *( KsecI * y(PQ)-y(N/4+PQ)) - Krxn * y(N/4+PQ)-2 * 
(1/(1+exp(-2*k*(y(N/4+PQ)-ys))))* Kag *(y(N/4+PQ))*(y(N/4+PQ)); 
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dydt(N/2+PQ) = C1 * (y(N/2+PQ-1) - 2 * y(N/2+PQ) + y(N/2+PQ)) - B1 * (-
y(N/2+PQ-1) + y(N/2+PQ)) - P * KovN *(KsecN * y(N/2+PQ) - y(3*N/4+PQ)) 
+ Krxn * y(PQ); 
    
    
dydt(3*N/4+PQ) = KovN *( KsecN * y(N/2+PQ) -y(3*N/4+PQ)) + Krxn * 
y(N/4+PQ); 
  
  
  
% Stage (PQ+1) AND (PQ+2)----------Feed point 
  
U = Q3 / (AREA * E); 
Dl = 10 * U * 17e-4 * E; 
B1 = U / (2 * h); 
C1 = Dl / (h ^ 2); 
B2 = U / (12 * h); 
C2 = Dl / (12 * h ^ 2); 
        
               
dydt(PQ+1) = C1 * ((Q2 * y(PQ) / Q3 + QF * CfI/Q3) - 2 * y(PQ+1) +  
y(PQ+2)) - B1 * (-(Q2 * y(PQ) / Q3 + QF * CfI / Q3) + y(PQ+2)) - P * 
KovI * (KsecI * y(PQ+1) - y(N/4+PQ+1)) - Krxn * y(PQ+1)-2 * (1/(1+exp(-
2*k*(y(PQ+1)-ys))))* Kag *(y(PQ+1))*(y(PQ+1)); 
    
          
dydt(N/4+PQ+1) = KovI * ( KsecI * y(PQ+1) - y(N/4+PQ+1)) - Krxn * 
y(N/4+PQ+1)-2 * (1/(1+exp(-2*k*(y(N/4+PQ+1)-ys))))* Kag 
*(y(N/4+PQ+1))*(y(N/4+PQ+1)); 
  
dydt(N/2+PQ+1) = C1 * ((Q2 * y(N/2+PQ) / Q3 + QF * CfN / Q3) - 2 * 
y(N/2+PQ+1) +  y(N/2+PQ+2)) - B1 * (-(Q2 * y(N/2+PQ) / Q3 + QF * CfN / 
Q3) + y(N/2+PQ+2)) - P * KovN * (KsecN * y(N/2+PQ+1) - y(3*N/4+PQ+1)) + 
Krxn * y(PQ+1); 
    
  
dydt(3*N/4+PQ+1) = KovN *( KsecN * y(N/2+PQ+1) - y(3*N/4+PQ+1)) + Krxn 
* y(N/4+PQ+1);  
  
  
dydt(PQ+2) = C2 * ( -(Q2 * y(PQ) / Q3 + QF * CfI / Q3)+ 16 * y(PQ+1) - 
30 * y(PQ+2) + 16 * y(PQ+3) - y(PQ+4)) - B2 * ((Q2*y(PQ)/Q3+QF*CfI/Q3) 
- 8 * y(PQ+1) + 8 * y(PQ+3) - y(PQ+4)) - P * KovI * (KsecI * y(PQ+2) - 
y(N/4+PQ+2)) - Krxn * y(PQ+2)-2 * (1/(1+exp(-2*k*(y(PQ+2)-ys))))* Kag 
*(y(PQ+2))*(y(PQ+2)); 
   
  
  
dydt(N/4+PQ+2) = KovI * ( KsecI * y(PQ+2) - y(N/4+PQ+2)) - Krxn * 
y(N/4+PQ+2)-2 * (1/(1+exp(-2*k*(y(N/4+PQ+2)-ys))))* Kag 
*(y(N/4+PQ+2))*(y(N/4+PQ+2)); 
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dydt(N/2+PQ+2) = C2 * (-(Q2 * y(N/2+PQ) / Q3 + QF * CfN / Q3) + 16 * 
y(N/2+PQ+1) - 30 * y(N/2+PQ+2) + 16 * y(N/2+PQ+3) - y(N/2+PQ+4)) - B2 * 
((Q2 * y(N/2+PQ) / Q3 + QF * CfN / Q3) - 8 * y(N/2+PQ+1) + 8 * 
y(N/2+PQ+3) - y(N/2+PQ+4))- P * KovN * (KsecN * y(N/2+PQ+2) - 
y(3*N/4+PQ+2)) + Krxn * y(PQ+2); 
   
    
dydt(3*N/4+PQ+2) = KovN *( KsecN * y(N/2+PQ+2) - y(3*N/4+PQ+2)) + Krxn 
* y(N/4+PQ+2); 
     
  
% Stage (PQ+3)-(PQR) -------Section 3 
  
for I=PQ+3:PQR 
  
dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) - 
y(I+2) )- B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI 
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)-
ys))))* Kag *(y(I))*(y(I)); 
     
  
dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 * 
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I)); 
  
  
dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16 
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 * 
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) + 
Krxn * y(I); 
     
        
dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn * 
y(N/4+I); 
  
end  
   
% Stage (PQR+1)-N/4-2-------section 4 
  
U = Q4 / (AREA * E); 
Dl = 10 * U * 17e-4 * E; 
B1 = U / (2 * h); 
C1 = Dl / (h ^ 2); 
B2 = U / (12 * h); 
C2 = Dl / (12 * h ^ 2); 
        
for I = PQR+1:N/4-2 
  
 dydt(I) = C2 * (- y (I-2) + 16 * y(I-1) - 30 * y(I) + 16 * y(I+1) - 
y(I+2)) - B2 * ( y(I-2) - 8 * y(I-1) + 8 * y(I+1) - y(I+2)) - P * KovI 
* (KsecI * y(I) - y(N/4+I)) - Krxn * y(I)-2 * (1/(1+exp(-2*k*(y(I)-
ys))))* Kag *(y(I))*(y(I)); 
  
     
 109 
 
dydt(N/4+I) = KovI *( KsecI * y(I) - y(N/4+I)) - Krxn * y(N/4+I)-2 * 
(1/(1+exp(-2*k*(y(N/4+I)-ys))))* Kag *(y(N/4+I))*(y(N/4+I)); 
  
  
dydt(N/2+I) = C2 * (- y(N/2+I-2) + 16 * y(N/2+I-1) - 30 * y(N/2+I) + 16 
* y(N/2+I+1) - y(N/2+I+2) ) - B2 * (y(N/2+I-2) - 8 * y(N/2+I-1) + 8 * 
y(N/2+I+1) - y(N/2+I+2)) - P * KovN * (KsecN * y(N/2+I) - y(3*N/4+I)) + 
Krxn * y(I); 
     
        
dydt(3*N/4+I) = KovN *( KsecN * y(N/2+I) - y(3*N/4+I)) + Krxn * 
y(N/4+I); 
    
 end 
  
% last stage ----------Section 4 
  
dydt(N/4-1) = C2 * (- y(N/4-3) + 16 * y(N/4-2) - 30 * y(N/4-1) + 16 * 
y(N/4) - y(N/4)) - B2 * (y(N/4-3) - 8 * y(N/4-2) + 8 * y(N/4) - y(N/4)) 
- P * KovI * (KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/4-1)-2* 
(1/(1+exp(-2*k*(y(N/4-1)-ys))))* Kag *(y(N/4-1))*(y(N/4-1)); 
     
  
dydt(N/2-1) = KovI *( KsecI * y(N/4-1) - y(N/2-1)) - Krxn * y(N/2-1)-2 
* (1/(1+exp(-2*k*(y(N/2-1)-ys))))* Kag *(y(N/2-1))*(y(N/2-1)); 
  
  
dydt(3*N/4-1) = C2 * (- y(3*N/4-3) + 16 * y(3*N/4-2) - 30 * y(3*N/4-1) 
+ 16 * y(3*N/4) - y(3*N/4)) - B2 * (y(3*N/4-3) - 8 * y(3*N/4-2) + 8 * 
y(3*N/4) - y(3*N/4)) - P * KovN * (KsecN * y(3*N/4-1) - y(N-1)) + Krxn 
* y(N/4-1); 
     
  
dydt(N-1) = KovN *( KsecN * y(3*N/4-1) -y(N-1)) + Krxn * y(N/2-1); 
  
       
dydt(N/4) = C1 * (y(N/4-1) -2 * y(N/4) +  y(N/4)) - B1 * (- y(N/4-1) + 
y(N/4)) - P * KovI * (KsecI * y(N/4) - y(N/2)) - Krxn * y(N/4)- 2 * 
(1/(1+exp(-2*k*(y(N/4)-ys))))* Kag *(y(N/4))*(y(N/4)); 
      
  
  
dydt(N/2) = KovI *( KsecI * y(N/4) - y(N/2)) - Krxn * y(N/2)-2 * 
(1/(1+exp(-2*k*(y(N/2)-ys))))* Kag *(y(N/2))*(y(N/2)); 
  
dydt(3*N/4) = C1 * (y(3*N/4-1) - 2 * y(3*N/4) + y(3*N/4)) - B1 * (-
y(3*N/4-1) + y(3*N/4)) - P * KovN *(KsecN * y(3*N/4) - y(N)) + Krxn * 
y(N/4); 
    
  
dydt(N) = KovN *( KsecN * y(3*N/4) - y(N)) + Krxn * y(N/2); 
  
 110 
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